Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab

Authors: A. Pawsey, P. Mahalingam, N. Senthivel, A. Ramessur, E. Turnbull, S. Usman, R. Browne, A. Patel, A. Stewart, L. Tookman, N. Counsell, R. Miller, S. Nicum, G. Eminowicz

Source: Опухоли женской репродуктивной системы, Vol 21, Iss 1, Pp 123-131 (2025)

Subject Terms: рак эндометрия, ленватиниб, пембролизумаб, переносимость, токсичность, Gynecology and obstetrics, RG1-991

File Description: electronic resource

Relation: https://ojrs.abvpress.ru/ojrs/article/view/1354; https://doaj.org/toc/1994-4098; https://doaj.org/toc/1999-8627

Access URL: https://doaj.org/article/6e274a68294e4750bb7e0ba4cbc3ebbe

Effectiveness of pembrolizumab in therapy of sarcomatoid variant of metastatic urothelial carcinoma. Clinical case ; Эффективность пембролизумаба в терапии саркоматоидного варианта метастатической уротелиальной карциномы. Клинический случай

Authors: A. S. Polyakova, E. A. Sokolov, D. Yu. Pushkar, А. С. Полякова, Е. А. Соколов, Д. Ю. Пушкарь

Source: Cancer Urology; Том 20, № 4 (2024); 104-111 ; Онкоурология; Том 20, № 4 (2024); 104-111 ; 1996-1812 ; 1726-9776

Subject Terms: саркоматоидный рак, bladder cancer, immunotherapy, pembrolizumab, sarcomatoid carcinoma, рак мочевого пузыря, иммунотерапия, пембролизумаб

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1857/1579; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1570; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1571; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1572; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1573; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1574; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1575; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1576; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1577; Lenis A.T., Lec P.M., Chamie K., Mshs M.D. Bladder cancer: a review. JAMA 2020;324(19):1980–91. DOI:10.1001/jama.2020.17598; Gu L., Ai Q., Cheng Q. et al. Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta­analysis of the clinicopathological features and survival outcomes. Cancer Cell Int 2020;20(1):550. DOI:10.1186/s12935­020­01626­9; Sui W., Matulay J.T., Onyeji I.C. et al. Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer. World J Urol 2017;35(7):1055–61. DOI:10.1007/s00345­016­1962­8; Konala V.M., Adapa S., Aronow W.S. Immunotherapy in bladder cancer. Am J Ther 2022;29(3):e334–7. DOI:10.1097/MJT.0000000000000934; Evans S.T., Jani Y., Jansen C.S. et al. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biol Ther 2024;25(1):2342599. DOI:10.1080/15384047.2024.2342599; Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second­ line line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI:10.1056/NEJMoa1613683; Miller N.J., Khaki A.R., Diamantopoulos L.N. et al. Histological subtypes and response to PD­1/PD­L1 blockade in advanced urothelial cancer: a retrospective Study. J Urol 2020;204(1):63–70. DOI:10.1097/JU.0000000000000761; Kobayashi T., Ito K., Kojima T. et al.; Japan Urological Oncology Group. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci 2021;112(2):760–73. DOI:10.1111/cas.14762; Iacovelli R., Ciccarese C., Bria E. et al. Patients with sarcomatoid renal cell carcinoma – re­defining the first­line of treatment: a meta­analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer 2020;136:195–203. DOI:10.1016/j.ejca.2020.06.008; Kotlowska M.P., Rueda A.G., Olmedo M.E. et al. Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review. Respir Med Case Rep 2019;26:310–4. DOI:10.1016/j.rmcr.2019.02.017; Tsurumi K., Kawashima Y., Akahira J. et al. A remarkable clinical response to pembrolizumab in a rare spindle cell carcinoma of the lung. JMA J 2020;3(1):83–6. DOI:10.31662/jmaj.2019­0015; Jin C., Yang B. Dramatic response of pulmonary sarcomatoid carcinoma to nivolumab combined with anlotinib: a case report. Case Rep Oncol 2020;13(2):601–5. DOI:10.1159/000507568; Li H., Zhang Q., Shuman L. et al. Evaluation of PD­L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. Sci Rep 2020;10(1):1439. DOI:10.1038/s41598­020­58351­6; Murase K., Nakane K., Kawase M. et al. Metastatic urothelial carcinoma with sarcomatoid subtype after robot­assisted radical cystectomy successfully treated with pembrolizumab. Cureus 2024;16(6):e61871. DOI:10.7759/cureus.61871; https://oncourology.abvpress.ru/oncur/article/view/1857

Availability: https://oncourology.abvpress.ru/oncur/article/view/1857
https://doi.org/10.17650/1726-9776-2024-20-4-104-111

Clinical and economic effectiveness of using immunotherapeutic drugs in patients with urothelial carcinoma in the healthcare system of the Russian Federation ; Клинико-экономическая эффективность использования иммунотерапевтических препаратов у пациентов с уротелиальным раком в условиях системы здравоохранения России

Authors: I. S. Krysanov, E. V. Makarova, D. V. Kurkin, V. Yu. Ermakova, И. С. Крысанов, Е. В. Макарова, Д. В. Куркин, В. Ю. Ермакова

Source: Cancer Urology; Том 19, № 4 (2023); 104-113 ; Онкоурология; Том 19, № 4 (2023); 104-113 ; 1996-1812 ; 1726-9776

Subject Terms: иммунотерапия, atezolizumab, pembrolizumab, avelumab, carboplatin, gemcitabine, immunotherapy, атезолизумаб, пембролизумаб, авелумаб, карбоплатин, гемцитамин

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1789/1497; Kaseb H., Aeddula N.R. Bladder Cancer. 2022. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK536923/.; Состояние онкологической помощи населению России в 2020 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 239 с.; Рак мочевого пузыря. Клинические рекомендации 2022.; Гладков О.А., Матвеев В.Б., Митин Т. и др. Практические рекомендации по лекарственному лечению рака мочевого пузыря. Злокачественные опухоли: Практические рекомендации RUSSCO 2020;10(3s2-1):542–55. DOI:10.18027/2224-5057-2020-10-3s2-32; Cathomas R., Lorch A., Bruins H.M. et al. EAU Muscle-invasive, Metastatic Bladder Cancer Guidelines Panel. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur Urol 2022;81(1):95–103. DOI:10.1016/j.eururo.2021.09.026; Do O.A., Ferris L.A., Holt S.K. et al. Treatment of metastatic urothelial carcinoma after previous cisplatin-based chemotherapy for localized disease: a retrospective comparison of different chemotherapy regimens. Clin Genitourin Cancer 2021;19(2):125–34. DOI:10.1016/j.clgc.2020.10.006; Logothetis C.J., Dexeus F.H., Finn L. et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8(6):1050–5. DOI:10.1200/JCO.1990.8.6.1050; Fischer C., Hofmann R., Hegele A. Chemotherapy of locally advanced or metastatic urothelial cell carcinoma: monocentric real-life data. Cancer Manag Res 2020;12:5077–84. DOI:10.2147/CMAR.S231508; Qu H.C., Huang Y., Mu Z.Y. et al. Efficacy and safety of chemotherapy regimens in advanced or metastatic bladder and urothelial carcinomas: an updated network meta-analysis. Front Pharmacol 2020 15;10:1507. DOI:10.3389/fphar.2019.01507; Galsky M.D., Stensland K.D., Moshier E. et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol 2016;34(8):825–32. DOI:10.1200/JCO.2015.64.1076; Болотина Л.В., Королева Л.А. Современные подходы к лекарственной терапии рака мочевого пузыря после первого прогрессирования. Research and Practical Medicine Journal (Исследования и практика в медицине) 2015;2(2):29–34. DOI:10.17709/2409-2231-2015-2-2-29-34; Омельяновский В.В., Авксентьева М.В., Сура М.В. и др. Методические рекомендации по проведению сравнительной клинико-экономической оценки лекарственного препарата (новая редакция). М., 2019.; Омельяновский В.В., Авксентьева М.В., Хачатрян Г.Р. и др. Методические рекомендации по использованию математического моделирования в клинико-экономических исследованиях и исследованиях с использованием анализа влияния на бюджет. М., 2019.; Von der Maase H., Sengelov L., Roberts J.T. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23(21):4602–8. DOI:10.1200/JCO.2005.07.757; De Santis M., Bellmunt J., Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/ carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30(2):191–9. DOI:10.1200/JCO.2011.37.3571; Vuky J., Balar A.V., Castellano D. et al. Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol 2020;38(23):2658–66. DOI:10.1200/JCO.19.01213; Balar A.V., Galsky M.D., Rosenberg J.E. et al. IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389(10064):67–76. DOI:10.1016/S0140-6736(16)32455-2; Powles T., Park S.H., Voog E. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383(13):1218–30. DOI:10.1056/NEJMoa2002788; Государственный реестр предельных отпускных цен, 2023. Доступно по: http://www.grls.rosminzdrav.ru/Default.aspx.; Sung H.H., Kim H., Kim R. et al. Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder. Investig Clin Urol 2022;63(2):168–74. DOI:10.4111/icu.20210407; Bellmunt J., de Wit R., Vaughn D.J. et al. KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI:10.1056/NEJMoa1613683; Письмо Минздрава России от 26.01.2023 № 31-2/И/2-1075 «О методических рекомендациях по способам оплаты медицинской помощи за счет средств обязательного медицинского страхования».; Ягудина Р.И., Серпик В.Г., Бабий В.В., Угрехелидзе Д.Т. Критерии эффективности в фармакоэкономическом анализе. Фармакоэкономика: теория и практика 2014;5(3):5–10.; Омельяновский В.В., Авксентьева М.В., Сура М.В. и др. Методические рекомендации по расчету затрат при проведении клинико-экономических исследований лекарственных препаратов. М., 2017.; https://oncourology.abvpress.ru/oncur/article/view/1789

Availability: https://oncourology.abvpress.ru/oncur/article/view/1789
https://doi.org/10.17650/1726-9776-2023-19-4-104-113

Lenvatinib and pembrolizumab combination in metastatic renal cell carcinoma: experience of the Republic of Bashkortostan ; Комбинация ленватиниба с пембролизумабом при метастатическом почечно-клеточном раке: опыт Республики Башкортостан

Authors: K. V. Menshikov, D. O. Lipatov, A. F. Nasretdinov, Sh. I. Musin, N. I. Sultanbaeva, I. A. Menshikova, A. V. Sultanbaev, A. A. Izmaylov, Sh. N. Galimov, A. Sh. Rezyapova, К. В. Меньшиков, Д. О. Липатов, A. Ф. Насретдинов, Ш. И. Мусин, Н. И. Султанбаева, И. А. Меньшикова, А. В. Султанбаев, А. А. Измайлов, Ш. Н. Галимов, А. Ш. Резяпова

Contributors: The article issue supported by Eisai Co., Ltd., Статья опубликована при поддержке Eisai Co., Ltd.

Source: Cancer Urology; Том 20, № 2 (2024); 26-34 ; Онкоурология; Том 20, № 2 (2024); 26-34 ; 1996-1812 ; 1726-9776

Subject Terms: реальная клиническая практика, pembrolizumab, renal cell carcinoma, real clinical practice, пембролизумаб, почечно-клеточный рак

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1835/1531; Miller K.D., Goding Sauer A., Ortiz A.P. et al. Cancer statistics for hispanics/latinos, 2018. CA. Cancer J Clin 2018;68(6):425–45. DOI:10.3322/caac.21494; Hsieh J.J., Purdue M.P., Signoretti S. et al. Renal cell carcinoma. Nat Rev Dis Primers 2017;3(1):1–19. DOI:10.1038/nrdp.2017.9; Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI:10.3322/caac.21492; Ljungberg B., Campbell S.C., Cho H.Y. et al. The epidemiology of renal cell carcinoma. Eur Urol 2011;60(4):615–21. DOI:10.1016/j.eururo.2011.06.049; Kane C.J., Mallin K., Ritchey J. et al. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 2008;113(1):78–83. DOI:10.1002/cncr.23518; Rossi S.H., Klatte T., Usher-Smith J., Stewart G.D. Epidemiology and screening for renal cancer. World J Urol 2018;36(9):1341–53. DOI:10.1007/s00345-018-2286-7; Capitanio U., Bensalah K., Bex A. et al. Epidemiology of renal cell carcinoma. Eur Urol 2019;75(1):74–84. DOI:10.1016/j.eururo.2018.08.036; Medina-Rico M., Ramos H.L., Lobo M. et al. Epidemiology of renal cancer in developing countries: Review of the literature. Can Urol Assoc J 2018;12(3):E154. DOI:10.5489/cuaj.4464; Vasudev N.S., Wilson M., Stewart G.D. et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open 2020;10(5):e035938. DOI:10.1136/bmjopen-2019-035938; Pavlakis G.M., Sakorafas G.H., Anagnostopoulos G.K. Intestinal metastases from renal cell carcinoma: a rare cause of intestinal obstruction and bleeding. Mt Sinai J Med 2004;71(2):127–30.; Speed J.M., Trinh Q.D., Choueiri T.K., Sun M. Recurrence in localized renal cell carcinoma: a systematic review of contemporary data. Curr Urol Rep 2017;18(2):15. DOI:10.1007/s11934-017-0661-3; Terrone C., Cracco C., Porpiglia F. et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 2006;49:324–31. DOI:10.1016/j.eururo.2005.11.014; Tsui K.H., Shvarts O., Smith R.B. et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163(4):1090–5 quiz 1295. DOI:10.1016/s0022-5347(05)67699-9; Wang L.L., Saidian A., Pan E. et al. Adjuvant therapy in renal cell carcinoma: are we ready for prime time? Kidney Cancer 2023;7:1–11.; Mir M.C., Derweesh I., Porpiglia F. et al. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol 207;71(4):606–17. DOI:10.1016/j.eururo.2016.08.060; Dhanji S., Wang L., Liu F. et al. Recent advances in the management of localized and locally advanced renal cell carcinoma: a narrative review. Res Rep Urol 2023;15:99–108. DOI:10.2147/RRU.S326987; Yim K., Aron M., Rha K.H. et al. Outcomes of robotassisted partial nephrectomy for clinical T3a renal masses: a multicenter analysis. Eur Urol Focus 2021;7(5):1107–14. DOI:10.1016/j.euf.2020.10.011; Andrade H.S., Zargar H., Akca O. et al. Is robotic partial nephrectomy safe for T3a renal cell carcinoma? Experience of a high-volume center. J Endourol 2017;31(2):153–7. DOI:10.1089/end.2016.0622; Campbell S.C., Clark P.E., Chang S.S. et al. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part I. J Urol 2021;206(2):199–208. DOI:10.1097/JU.0000000000001911; Pierorazio P.M., Johnson M.H., Patel H.D. et al. AHRQ comparative effectiveness reviews. In Management of renal masses and localized renal cancer. Rockville (MD): Agency for Healthcare Research and Quality (US) 2016.; Pierorazio P.M., Johnson M.H., Patel H.D. et al. Management of renal masses and localized renal cancer: systematic review and meta-analysis. J Urol 2016;196(4):989–99. DOI:10.1016/j.juro.2016.04.081; Bukavina L., Bensalah K., Bray F. et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol 2022;82(5):529–42. DOI:10.1016/j.eururo.2022.08.019; Barata P.C., Rini B.I. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin 2017;67(6):507–24. DOI:10.3322/caac.21411; Attalla K., Weng S., Voss M.H., Hakimi A.A. Epidemiology, risk assessment, and biomarkers for patients with advanced renal cell carcinoma. Urol Clin 2020;47(3):293–303. DOI:10.1016/j.ucl.2020.04.002; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2017. CA A Cancer J. Clin 2017;67(1):7–30. DOI:10.3322/caac.21387; He Y., Luo Y., Huang L. et al. New frontiers against sorafenib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Pharmacol Res 2021;170:105732. DOI:10.1016/j.phrs.2021.105732; Gong C., Ji Q., Wu M. et al. Ferroptosis in tumor immunity and therapy. J Cell Mol Med 2022;26(22):5565–79. DOI:10.1111/jcmm.17529; Meng Y., Sun H., Li Y. et al. Targeting ferroptosis by ubiquitin system enzymes: a potential therapeutic strategy in cancer. Int J Biol Sci 2022;18(14):5475–88. DOI:10.7150/ijbs.73790; Motzer R., Alekseev B., Rha S.Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384:1289–300. DOI:10.1056/NEJMoa2035716; Dudani S., de Velasco G., Wells J.C. et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open 2021;4:e2021869. DOI:10.1001/jamanetworkopen.2020.21869; Wei H., Miao J., Cui J. et al. The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database. Sci Rep 2021;11:17822. DOI:10.1038/s41598-021-97365-6; Hahn A.W., Lebenthal J., Genovese G. et al. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. DOI:10.1016/j.ctarc.2022.100640; Grünwald V., Powles T., Eto M. et al. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol 2023 16;13:1223282. DOI:10.3389/fonc.2023.1223282 (Erratum in: Front Oncol 2024;13:1343027. DOI:10.3389/fonc.2023.1343027); https://oncourology.abvpress.ru/oncur/article/view/1835

Availability: https://oncourology.abvpress.ru/oncur/article/view/1835
https://doi.org/10.17650/1726-9776-2024-20-2-26-34

Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma ; Эффективность комбинации ленватиниба с пембролизумабом у больных распространенным почечно-клеточным раком

Authors: M. I. Volkova, A. S. Kalpinskiy, О. A. Goncharova, К. V. Menshikov, O. A. Stativko, E. V. Karabina, A. S. Dergunov, N. I. Polshina, E. N. Aleksandrova, A. A. Lebedinets, A. K. Panov, A. V. Sultanbaev, E. A. Usynin, M. V. Volkonsky, V. V. Mikhalyuk, R. A. Zukov, Yu. V. Anzhiganova, M. A. Gusniev, E. N. Igumnova, S. V. Kuzmicheva, I. A. Pokataev, A. S. Olshanskaya, N. I. Pervakova, E. L. Parsadanova, T. A. Sannikova, A. A. Bystrov, D. M. Dubovichenko, M. R. Mukhitova, V. A. Chubenko, K. A. Shkret, M. N. Gorshenina, A. V. Semenov, M. K. Davlatova, A. E. Kosareva, O. A. Lutoshkina, O. A. Maslova, M. V. Makhnutina, A. V. Mishina, M. Zh. Murzalina, O. A. Podyacheva, S. A. Kalinin, O. A. Mailyan, A. R. Safarova, K. O. Semenova, M. A. Strokova, E. Yu. Urashkina, O. S. Shmygina, O. Yu. Novikova, М. И. Волкова, А. С. Калпинский, О. А. Гончарова, К. В. Меньшиков, О. А. Стативко, Е. В. Карабина, А. С. Дергунов, Н. И. Польшина, Е. Н. Александрова, А. А. Лебединец, А. К. Панов, А. В. Султанбаев, Е. А. Усынин, М. В. Волконский, В. В. Михалюк, Р. А. Зуков, Ю. В. Анжиганова, М. А. Гусниев, Е. Н. Игумнова, С. В. Кузьмичева, И. А. Покатаев, А. С. Ольшанская, Н. И. Первакова, Э. Л. Парсаданова, Т. А. Санникова, А. А. Быстров, Д. М. Дубовиченко, М. Р. Мухитова, В. А. Чубенко, К. А. Шкрет, М. Н. Горшенина, А. В. Семенов, М. К. Давлатова, А. Е. Косарева, О. А. Лутошкина, О. А. Маслова, М. В. Махнутина, А. В. Мишина, М. Ж. Мурзалина, О. А. Подъячева, С. А. Калинин, О. А. Маилян, А. Р. Сафарова, К. О. Семенова, М. А. Строкова, Е. Ю. Урашкина, О. С. Шмыгина, О. Ю. Новикова

Source: Cancer Urology; Том 20, № 3 (2024); 33-48 ; Онкоурология; Том 20, № 3 (2024); 33-48 ; 1996-1812 ; 1726-9776

Subject Terms: безопасность, lenvatinib, pembrolizumab, survival, objective response, safety, ленватиниб, пембролизумаб, выживаемость, объективный ответ

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1875/1555; Волкова М.И., Носов Д.А., Алексеев Б.Я. и др. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли: Практические рекомендации RUSSCO 2023;13(3s2):609–19.; Motzer R.J., Jonasch E., Agarwal N. et al. nccn clinical practice guidelines in oncology. Kidney Cancer – v.1.2025. July 1, 2024.; Motzer R., Alekseev B., Rha S.Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384(14):1289–300. DOI:10.1056/NEJMoa2035716; Motzer R.J., Porta C., Eto M. et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol 2024;42(11):1222–8. DOI:10.1200/JCO.23.01569; Albiges L., Gurney H., Atduev V. et.al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2023;24(8):881–91. DOI:10.1016/S1470-2045(23)00276-0; Voss M., Gurney H., Atduev V. et al. ASCO GU 2024: First-line pembrolizumab plus lenvatinib for non-clear cell RCC: extended follow-up of the phase 2 KEYNOTE-B61 study. Lancet Oncol 2023;24(8):881–91. DOI:10.1016/S1470-2045(23)00276-0; Волкова М.И., Калпинский А.С., Гончарова О.А. и др. Токсичность и безопасность комбинации ленватиниба с пембролизумабом у больных распространенным почечноклеточным раком. Современная онкология 2024;26(1):39–47.; Инструкция по медицинскому применению препарата ленватиниб. Регистрационный номер: ЛП-003398-060720.; Инструкция по медицинскому применению препарата пембролизумаб. Регистрационный номер: ЛП-008684, 2022.; Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47. DOI:10.1016/j.ejca.2008.10.026; Freites-Martinez A., Santana N., Arias-Santiago S., Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE – Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 2021;112(1):90–2. DOI:10.1016/j.ad.2019.05.00; Lee C.H., Yogesh Shah A., Rao A. et al. Final database lock results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma. Oncologist 2023;28(Suppl 1):S3–4.; Hamamoto S., Tasaki Y., Morikawa T. et al. Efficacy and safety of immuno-oncology plus tyrosine kinase inhibitors as late-line combination therapy for patients with advanced renal cell carcinoma. J Clin Med 2024;13(12):3365. DOI:10.3390/jcm13123365; Liu Y., Zhou L., Chen Y. et al. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. BMC Urol 2019;19(1):49. DOI:10.1186/s12894-019-0481-5; Волкова М.И., Калпинский А.С., Меньшиков К.В. и др. Эффективность и безопасность кабозантиниба у пациентов с распространенным почечно-клеточным раком: российcкое многоцентровое наблюдательное исследование. Онкоурология 2023;19(1):46–60. DOI:10.17650/1726-9776-2023-19-1-46-60; Ikeda T., Ishihara H., Nemoto Y. et al. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Urol Oncol 2021;39(10):735.e9–5. DOI:10.1016/j.urolonc.2021.05.012; Haight P.J., Brown M.D., Espelien B.M. et al. Predictors of toxicity and response to treatment with lenvatinib and pembrolizumab in patients with gynecologic malignancy. Presented at: Society of Gynecologic Oncology Winter Meeting; January 25–27, 2024; Olympic Valley, CA. Poster 509234.; https://oncourology.abvpress.ru/oncur/article/view/1875

Availability: https://oncourology.abvpress.ru/oncur/article/view/1875
https://doi.org/10.17650/1726-9776-2024-20-3-33-48

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms ; Исследование III фазы CLEAR у пациентов с распространенным почечно-клеточным раком: анализ в подгруппах больных, получавших ленватиниб с пембролизумабом и сунитиниб

Authors: V. Grünwald, T. Powles, M. Eto, E. Kopyltsov, S. Y. Rha, C. Porta, R. Motzer, T. E. Hutson, M. J. Méndez-Vidal, S. H. Hong, E. Winquist, J. C. Goh, P. Maroto, T. Buchler, T. Takagi, J. E. Burgents, R. Perini, C. He, C. E. Okpara, J. McKenzie, T. K. Choueiri

Contributors: Работа имела поддержку от Eisai Inc., Натли, штат Нью-Джерси, США, и Merck Sharp & Dohme LLC, дочерней компании Merck & Co., Inc., Рауэй, штат Нью-Джерси, США. Помощь в написании статьи была оказана Oxford PharmaGenesis Inc., Ньютаун, штат Пенсильвания, США. Статья имела финансирование от Eisai Inc., Натли, штат Нью-Джерси, США, и Merck Sharp & Dohme LLC, дочерней компании Merck & Co., Inc., Рауэй, штат Нью-Джерси, США. Пациентам, получавшим лечение в Мемориальном онкологическом центре им. Слоуна–Кеттеринга, оказывалась поддержка за счет гранта того же центра (P30 CA008748).

Source: Cancer Urology; Том 20, № 1 (2024); 24-35 ; Онкоурология; Том 20, № 1 (2024); 24-35 ; 1996-1812 ; 1726-9776

Subject Terms: саркоматоидный компонент, lenvatinib, pembrolizumab, sunitinib, bone metastasis, liver metastasis, lung metastasis, sarcomatoid histology, ленватиниб, пембролизумаб, сунитиниб, метастаз в костях, метастаз в печени, метастаз в легких

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1810/1529; Choueiri T.K., Motzer R.J. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017;376:354–66. DOI:10.1056/NEJMra1601333; Motzer R., Alekseev B., Rha S.Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384:1289–300. DOI:10.1056/NEJMoa2035716; Dudani S., de Velasco G., Wells J.C. et al. Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open 2021;4:e2021869. DOI:10.1001/jamanetworkopen.2020.21869; Wei H., Miao J., Cui J. et al. The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database. Sci Rep 2021;11:17822. DOI:10.1038/s41598-021-97365-6; Hahn A.W., Lebenthal J., Genovese G. et al. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. DOI:10.1016/j.ctarc.2022.100640; Bianchi M., Sun M., Jeldres C. et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012;23:973–80. DOI:10.1093/annonc/mdr362; National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Kidney Cancer. Available at: https://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf (accessed April 31, 2023).; Yue G., Deyu L., Lianyuan T. et al. Clinical features and prognostic factors of patients with metastatic renal cell carcinoma stratified by age. Aging (Albany NY) 2021;13:8290–305. DOI:10.18632/aging.202637; Chen S.C., Kuo P.L. Bone metastasis from renal cell carcinoma. Int J Mol Sci 2016;17:987. DOI:10.3390/ijms17060987; Coleman R., Hadji P., Body J.J. et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2020;31:1650–63. DOI:10.1016/j.annonc.2020.07.019; Rathmell W.K., Rumble R.B., Van Veldhuizen P.J. et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol 2022;40:2957–95. DOI:10.1200/JCO.22.00868; Hamada S., Ito K., Kuroda K. et al. Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis. Mol Clin Oncol 2015;3:63–8. DOI:10.3892/mco.2014.432; Leibovich B.C., Blute M.L., Cheville J.C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:1663–71. DOI:10.1002/cncr.11234; Bottiglieri A., Sepe P., Stellato M. et al. Optimal choice of adjuvant treatment for renal cell carcinoma following nephrectomy. Cancer Manag Res 2022;14:3071–81. DOI:10.2147/CMAR.S360441; Culp S.H., Tannir N.M., Abel E.J. et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010;116:3378–88. DOI:10.1002/cncr.25046; Gong J., Maia M.C., Dizman N. et al. Metastasis in renal cell carcinoma: biology and implications for therapy. Asian J Urol 2016;3:286–92. DOI:10.1016/j.ajur.2016.08.006; Motzer R.J., Banchereau R., Hamidi H. et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell 2020;38:803–17.e4. DOI:10.1016/j.ccell.2020.10.011; Choueiri T.K., Atkins M.B., Bakouny Z. et al. Summary from the first kidney cancer research summit, September 12–13, 2019: a focus on translational research. J Natl Cancer Inst 2021;113:234–43. DOI:10.1093/jnci/djaa064; Choueiri T.K., Powles T., Burotto M. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384:829–41. DOI:10.1056/NEJMoa2026982; Motzer R.J., Tannir N.M., McDermott D.F. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277–90. DOI:10.1056/NEJMoa1712126; Motzer R.J., Penkov K., Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1103–15. DOI:10.1056/NEJMoa1816047; Braun D.A., Bakouny Z., Hirsch L. et al. Beyond conventional immune-checkpoint inhibition – novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol 2021;18:199–214. DOI:10.1038/s41571-020-00455-z; Van Allen E.M., Choueiri T.K. Dissecting the immunogenomic biology of cancer for biomarker development. Nat Rev Clin Oncol 2021;18:133–4. DOI:10.1038/s41571-020-00461-1; Burke J.F., Sussman J.B., Kent D.M., Hayward R.A. Three simple rules to ensure reasonably credible subgroup analyses. BMJ 2015;351:h5651. DOI:10.1136/bmj.h5651; Ravi P., Bakouny Z., Schmidt A., Choueiri T.K. Novel therapeutic appro-aches and the evolution of drug development in advanced kidney cancer. Cancer J 2020;26:464–70. DOI:10.1097/PPO.0000000000000477; https://oncourology.abvpress.ru/oncur/article/view/1810

Availability: https://oncourology.abvpress.ru/oncur/article/view/1810
https://doi.org/10.17650/1726-9776-2024-20-1-24-35

Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study ; Сравнение комбинации ленватиниба и пембролизумаба с монотерапией сунитинибом у пациентов с распространенным почечно-клеточным раком: оценка выживаемости по степени ответа опухоли и эффективности лечения по критериям международного консорциума по лечению метастатического рака почки. Анализ результатов рандомизированного исследования III фазы CLEAR

Authors: V. Grünwald, T. Powles, E. Kopyltsov, V. Kozlov, T. Alonso-Gordoa, M. Eto, T. Hutson, R. Motzer, E. Winquist, P. Maroto, B. Keam, G. Procopio, S. Wong, B. Melichar, F. Rolland, M. Oya, K. Rodriguez-Lopez, K. Saito, J. McKenzie, C. Porta, Е. Kopyltsov, М. Eto

Contributors: Данное исследование было спонсировано Eisai Inc., Натли, Нью-Джерси, США и Merck Sharp & Dohme LLC – дочерняя компания Merck & Co., Inc., Рауэй, Нью-Джерси, США. Помощь в написании статьи финансировалась Eisai Inc., Натли, Нью-Джерси, США и Merck Sharp & Dohme LLC – дочерней компанией Merck & Co., Inc., Рауэй, Нью-Джерси, США. Пациентам, получавшим лечение в Мемориальном онкологическом центре им. Слоуна–Кеттеринга, частично оказывалась поддержка за счет гранта поддержки Мемориального онкологического центра им. Слоуна–Кеттеринга/Основного гранта (P30 CA008748)

Source: Cancer Urology; Том 19, № 4 (2023); 32-43 ; Онкоурология; Том 19, № 4 (2023); 32-43 ; 1996-1812 ; 1726-9776

Subject Terms: почечно-клеточный рак, pembrolizumab, sunitinib, depth of response, renal cell carcinoma, пембролизумаб, сунитиниб, степень ответа

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1786/1493; National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: kidney and renal pelvis cancer. Available at: https://seer.cancer.gov/statfacts/html/kidrp.html.; International Agency for Research on Cancer (IARC). GLOBOCAN 2020. Cancer Today. Available at: https://gco.iarc.fr/today/home.; Padala S.A., Barsouk A., Thandra K.C. et al. Epidemiology of renal cell carcinoma. World J Oncol 2020;11(3):79–87. DOI:10.14740/wjon1279; Li P., Wong Y.N., Armstrong K. et al. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med 2016;5(2):169–81. DOI:10.1002/cam4.574; Choueiri T.K., Motzer R.J. Systemic therapy for metastatic renalcell carcinoma. N Engl J Med 2017;376(4):354–66. DOI:10.1056/NEJMra1601333; Choueiri T.K., Kaelin Jr W.G. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med 2020;26(10):1519–30. DOI:10.1038/s41591-020-1093-z; Choueiri T.K., Powles T., Burotto M. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384(9):829–41. DOI:10.1056/NEJMoa2026982; Motzer R.J., Tannir N.M., McDermott D.F. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277–90. DOI:10.1056/NEJMoa1712126; Motzer R., Alekseev B., Rha S.Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384(14):1289–300. DOI:10.1056/NEJMoa2035716; Motzer R.J., Penkov K., Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103–15. DOI:10.1056/NEJMoa1816047; Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116–27. DOI:10.1056/NEJMoa1816714; Rassy E., Flippot R., Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol 2020;12:1758835920907504. DOI:10.1177/1758835920907504; National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN Guidelines). Kidney cancer. Version 3.2022. Available at: http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf.; Bedke J., Albiges L., Capitanio U. et al. Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma. Eur Urol 2021;79(3):339–42. DOI:10.1016/j.eururo.2020.12.005; Powles T., Albiges L., Bex A. et al. ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol 2021;32(12):1511–9. DOI:10.1016/j.annonc.2021.09.014; Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16(15):1473–82. DOI:10.1016/S1470-2045(15)00290-9; Pal S.K., Puente J., Heng D.Y.C. et al. Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI) [abstract]. J Clin Oncol 2021;39(6 Suppl):307.; Larkin J.M.G., Tykodi S.S., Donskov F. et al. First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): updated follow-up for KEYNOTE-427 cohort A. Ann Oncol 2019;30(Suppl 5):v381–2, Abstract 949P.; Lee J.L., Ziobro M., Gafanov R. et al. KEYNOTE-427 cohort B: first-line pembrolizumab (pembro) monotherapy for advanced nonclear cell renal cell carcinoma (NCC-RCC). J Clin Oncol 2019;37(15 Suppl):4569.; Lee C.H., Shah A.Y., Rasco D. et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol 2021;22(7):946–58. DOI:10.1016/S1470-2045(21)00241-2; Grünwald V., McKay R.R., Krajewski K.M. et al. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol 2015;67(5):952–8. DOI:10.1016/j.eururo.2014.12.036; Motzer R., Porta C., Alekseev B. et al. Health-related quality of life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib: a randomized phase 3 study (CLEAR trial). Lancet Oncol 2022;23(6):768–80. DOI:10.1016/S1470-2045(22)00212-1; Powles T., Plimack E.R., Soulières D. et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended followup from a randomised, open-label, phase 3 trial. Lancet Oncol 2020;21(12):1563–73. DOI:10.1016/S1470-2045(20)30436-8; Motzer R.J., Escudier B., McDermott D.F. et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer 2020;8(2):e000891. DOI:10.1136/jitc-2020-000891; Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from 42-month follow-up of KEYNOTE-426. J Clin Oncol 2021;39(15 Suppl):4500.; Haanen J.B.A.G., Larkin J., Choueiri T.K. et al. Efficacy of avelumabaxitinib (AAx) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101. J Clin Oncol 2021;39(15 Suppl):4574.; Albiges L., Tannir N.M., Burotto M. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5(6):e001079. DOI:10.1136/esmoopen-2020-001079; Leary A., Larkin J.M., Pickering L.M. Cytokine therapy for renal cell cancer: the evolving role of immunomodulation. Therapy 2011;8:347–58.; Fisher R.I., Rosenberg S.A., Fyfe G. Long-term survival update for highdose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(Suppl 1):S55–7.; https://oncourology.abvpress.ru/oncur/article/view/1786

Availability: https://oncourology.abvpress.ru/oncur/article/view/1786
https://doi.org/10.17650/1726-9776-2023-19-4-32-43

Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer ; Анапластический рак щитовидной железы: редкое клиническое наблюдение выраженного ответа на иммунотерапию

Authors: D. M. Vontlaya, O. V. Stryapikhina, A. A. Egorin, A. V. Logvinenko, R. I. Tamrazov, Д. М. Вонтлая, О. В. Стряпихина, А. А. Егорин, А. В. Логвиненко, Р. И. Тамразов

Source: Head and Neck Tumors (HNT); Том 14, № 1 (2024); 63-69 ; Опухоли головы и шеи; Том 14, № 1 (2024); 63-69 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2024-14-1

Subject Terms: пембролизумаб, thyroid gland, immunotherapy, pembrolizumab, щитовидная железа, иммунотерапия

File Description: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/970/621; Лукьянов С.А., Сергийко С.В., Титов С.Е. и др. Новые возможности дооперационной диагностики анапластического рака щитовидной железы. Опухоли головы и шеи 2021;11(1):34-40. DOI:10.17650/2222-1468-2021-11-1-34-40; Пылев А.Л., Жандарова А.А., Петров К.С. и др. Анапластический рак щитовидной железы. Есть ли свет в конце туннеля? Опухоли головы и шеи 2020;10(1):10-9. DOI:10.17650/2222-1468-2020-10-1-10-19; Никифорович П.А., Румянцев П.О., Слепцов И.В. и др. Лечение BRAFV600Е-позитивного анапластического рака щитовидной железы. Клиническое наблюдение. Сибирский онкологический журнал 2020;19(5):131-44. DOI:10.21294/1814-4861-2020-19-5-131-144; Мудунов А.М., Пхешхова Б.Г., Зейналова П.А. и др. Сложности диагностики и особенности клинического течения анапластического рака щитовидной железы. Клинический случай. MD-Onco 2022;2(4):22-6. DOI:10.17650/2782-3202-2022-2-4-22-26; Samsonov R., Burdakov V., Shtam T. et al. Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer. Tumour Biol 2016;37(9):12011-21. DOI:10.1007/s13277-016-5065-3; Volante M., Lam A.K., Papotti M. et al. Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know? Endocr Pathol 2021;32(1):63-76. DOI:10.1007/s12022-021-09665-2; Santhanam P., Khthir R., Solnes L.B., Ladenson P.W. The relationship of BRAFv600e mutation status to FDG PET/CT avidity in thyroid cancer: a review and meta-analysis. Endocr Pract 2018;24(1):21-6. DOI:10.4158/EP-2017-0080; FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAFV600E mutation. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenibplus-trametinib-anaplastic-thyroid-cancer-braf-v600e-mutation.; Naing A., Gainor J.F., Gelderblom H. et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer 2020;8(1):e000530. DOI:10.1136/jitc-2020-000530; Cabanillas M.E., Dadu R., Iyer P. et al. Acquired secondary RAS mutation in BRAFV600E-mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid 2020;30(9):1288-96. DOI:10.1089/thy.2019.0514; Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64.; Edwards S.C., Hoevenaar W.H.M., Coffelt S.B. Emerging immunotherapies for metastasis. Br J Cancer 2021;124(1):37-48. DOI:10.1038/s41416-020-01160-5; Larkin J., Chiarion-Sileni V., Gonzalez R. et al. Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma. N Engl J Med 2015;373(1):23-34. DOI:10.1056/NEJMoa1504030; Borel C., Jung A.C., Burgy M. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Cancer 2020;12(9):2691. DOI:10.3390/cancers12092691; https://ogsh.abvpress.ru/jour/article/view/970

Availability: https://ogsh.abvpress.ru/jour/article/view/970
https://doi.org/10.17650/2222-1468-2024-14-1-63-69

The results of immunotherapy in patients with recurrent and metastatic human papilloma virus positive head and neck squamous cell carcinoma ; Влияние ассоциированности опухоли с вирусом папилломы человека на результаты иммунотерапии у пациентов с рецидивным и метастатическим плоскоклеточным раком головы и шеи

Authors: A. V. Ignatova, Yu. V. Alymov, А. В. Игнатова, Ю. В. Алымов

Source: Head and Neck Tumors (HNT); Том 14, № 1 (2024); 39-48 ; Опухоли головы и шеи; Том 14, № 1 (2024); 39-48 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2024-14-1

Subject Terms: ниволумаб, head and neck squamous cell carcinoma, oropharyngeal squamous cell carcinoma, targeted therapy, immunotherapy, programmed death-ligand 1, pembrolizumab, nivolumab, плоскоклеточный рак головы и шеи, плоскоклеточный рак ротоглотки, таргетная терапия, иммунотерапия, лиганд рецептора программируемой клеточной гибели 1, пембролизумаб

File Description: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/967/618; De Sanjose S., Quint W.G., Alemany L. et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11(11):1048—56. DOI:10.1016/S1470-2045(10)70230-8; Chaturvedi A.K., Engels E.A., Pfeiffer R.M. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29(32):4294-301. DOI:10.1200/JCO.2011.36.4596; Nasman A., Attner P., Hammarstedt L. et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125(2):362-6. DOI:10.1002/ijc.24339; Gillison M.L., Broutian T., Pickard R.K. et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012;307(7):693-703. DOI:10.1001/jama.2012.101; Mehanna H., Beech T., Nicholson T. et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer - systematic review and meta-analysis of trends by time and region. Head Neck 2013;35(5):747-55. DOI:10.1002/hed.22015; Marklund L., Holzhauser S., de Flon C. et al. Survival of patients with oropharyngeal squamous cell carcinomas (OPSCC) in relation to TNM 8 - risk of incorrect downstaging of HPV-mediated non- tonsillar, non-base of tongue carcinomas. Eur J Cancer 2020;139:192-200. DOI:10.1016/j.ejca.2020.08.003; Gillison M.L., Koch W.M., Capone R.B. et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92(9):709-20. DOI:10.1093/jnci/92.9.709; Amin M., Edge S., Greene F. et al. AJCC Cancer Staging Manual, 8th edn. New York: Springer, 2017.; Masterson L., Moualed D., Liu Z.W. et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur J Cancer 2014;50(15):2636-48. DOI:10.1016/j.ejca.2014.07.001; Economopoulou P., Kotsantis I., Psyrri A. Special issue about head and neck cancers: HPV positive cancers. Int J Mol Sci 2020;21(9):3388. DOI:10.3390/ijms21093388; Gillison M.L., Trotti A.M., Harris J. et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2019;393(10166):40-50. DOI:10.1016/s0140-6736(18)32779-x; Liu C., Mann D., Sinha U.K., Kokot N.C. The molecular mechanisms of increased radiosensitivity of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC): an extensive review. J Otolaryngol Head Neck Surg 2018;47(1):59. DOI:10.1186/s40463-018-0302-y; Ang K.K., Harris J., Wheeler R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24-35. DOI:10.1056/NEJMoa0912217; Posner M.R., Lorch J.H., Goloubeva O. et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011;22(5):1071-7. DOI:10.1093/annonc/mdr006; Roselló À., Albuquerque R., Roselló-Llabrés X. et al. Transoral robotic surgery vs open surgery in head and neck cancer. A systematic review of the literature. Med Oral Patol Oral Cir Bucal 2020;25(5):e599-607. DOI:10.4317/medoral.23632; Economopoulou P., De Bree R., Kotsantis I., Psyrri A. Diagnostic tumor markers in head and neck squamous cell carcinoma (HNSCC) in the clinical setting. Front Oncol 2019;9:827. DOI:10.3389/fonc.2019.00827; Bossi P., Miceli R., Benasso M. et al. Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials. Head Neck 2018;40(12):2648-56. DOI:10.1002/hed.25389; Szturz P., Wouters K., Kiyota N. et al. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist 2017;22(9):1056-66. DOI:10.1634/theoncologist.2017-0015; Vermorken J.B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27. DOI:10.1056/NEJMoa0802656; Mehanna H., Robinson M., Hartley A. et al. On behalf of the de-escalate HPV trial group. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus - positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 2019;393(10166):51-60. DOI:10.1016/S0140-6736(18)32752-1; Gleber-Netto F.O., Rao X., Guo T. et al. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight 2019;4(1):e124762. DOI:10.1172/jci.insight.124762; Brennan S., Baird A.M., O'Regan E., Sheils O. The role of human papilloma virus in dictating outcomes in head and neck squamous cell carcinoma. Front Mol Biosci 2021;8:677900. DOI:10.3389/fmolb.2021.677900; Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576-82. DOI:10.1038/nature14129; Reder H., Wagner S., Gamerdinger U. et al. Genetic alterations in human papillomavirus-associated oropharyngeal squamous cell carcinoma of patients with treatment failure. Oral Oncol 2019;93:59-65. DOI:10.1016/j.oraloncology.2019.04.013; Harbison R.A., Kubik M., Konnick E.Q. et al. The mutational landscape of recurrent versus nonrecurrent human papillomavirus- related oropharyngeal cancer. JCI Insight 2018;3(14):e99327. DOI:10.1172/jci.insight.99327; Isaacsson Velho P.H., Castro G., Chung C.H. Targeting the PI3K pathway in head and neck squamous cell carcinoma. Am Soc Clin Oncol Educ Book 2015:123-8. DOI:10.14694/EdBook_AM.2015.35.123; Lechien J.R., Seminerio I., Descamps G. et al. Impact of HPV infection on the immune system in oropharyngeal and non- oropharyngeal squamous cell carcinoma: a systematic review. Cells 2019;8(9):1061. DOI:10.3390/cells8091061; Turksma A.W., Bontkes H.J., van den Heuvel H. et al. Effector memory T-cell frequencies in relation to tumour stage, location and HPV status in HNSCC patients. Oral Dis 2013;19(6):577-84. DOI:10.1111/odi.12037; Kareer R., Ahuja S., Chaudhary N., Arora R. Association of PD-L1 and p16 expression with clinicopathological parameters in oral cavity and oropharyngeal squamous cell carcinoma. Pathol Res Pract 2023;241:154266. DOI:10.1016/j.prp.2022.154266; Machiels J.P., Rene Leemans C., Golusinski W. et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(11):1462-75. DOI:10.1016/j.annonc.2020.07.011; Mandal R., §enbabaoglu Y., Desrichard A. et al. The Head and Neck Cancer Immune Landscape and its Immunotherapeutic Implications. JCI Insight 2016;1(17):e89829. DOI:10.1172/jci.insight.89829; Wang Y., Xu Y., Hua Q. et al. Novel prognostic model based on im-mune signature for head and neck squamous cell carcinoma. BioMed Res Int 2020;2020:4725314. DOI:10.1155/2020/4725314; Zhang F., Liu Y., Yang Y., Yang K. Development and Validation of a fourteen-innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma. BMC Cancer 2020;20(1):1015. DOI:10.1186/s12885-020-07489-7; Varilla V., Atienza J., Dasanu C.A. Immune alterations and immunotherapy prospects in head and neck cancer. Expert Opin Biol Ther 2013;13(9):1241-56. DOI:10.1517/14712598.2013.810716; Wang H., Zhao Q., Zhang Y. et al. Immunotherapy advances in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma and its relationship with human papillomavirus. Front Immunol 2021;12:652054. DOI:10.3389/fimmu.2021.652054; Clancy K., Hamill C.S., O'Neill W.Q. et al. Impact of p16 status and anatomical site in anti-PD-1 immunotherapy-treated recurrent/ metastatic head and neck squamous cell carcinoma patients. Cancers (Basel) 2021;13(19):4861. DOI:10.3390/cancers13194861; Kanaan H., Kourie H.R., Awada A.H. Are virus-induced cancers more sensitive to checkpoint inhibitors? Future Oncol 2016;12(23):2665-8. DOI:10.2217/fon-2016-028; Näsman A., Romanitan M., Nordfors C. et al. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One 2012;7(6):e38711. DOI:10.1371/journal.pone.0038711; Green V.L., Michno A., Stafford N.D., Greenman J. Increased prevalence of tumour infiltrating immune cells in oropharyngeal tumours in comparison to other subsites: relationship to peripheral immunity. Cancer Immunol Immunother 2013;62(5):863-73. DOI:10.1007/s00262-013-1395-9; Matlung S.E., Wilhelmina van Kempen P.M., Bovenschen N. et al. Differences in T-cell infiltrates and survival between HPV+ and HPV- oropharyngeal squamous cell carcinoma. Future Sci OA 2016;2(1):Fso88. DOI:10.4155/fso.15.88; Welters M.J.P., Ma W., Santegoets S. et al. Intratumoral HPV16- specific T cells constitute a type i-oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer. Clin Cancer Res 2018;24(3):634-47. DOI:10.1158/1078-0432.CCR-17-2140; Heusinkveld M., Goedemans R., Briet R.J. et al. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer 2012;131(2):E74-85. DOI:10.1002/ijc.26497; Wood O., Woo J., Seumois G. et al. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. Oncotarget 2016;7(35):56781-97. DOI:10.18632/oncotarget.10788; Schoenfeld J.D., Gjini E., Rodig S.J. et al. Evaluating the PD-1 axis and immune effector cell infiltration in oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2018;102(1):137-45. DOI:10.1016/j.ijrobp.2018.05.002; Oliveira-Costa J.P., de Carvalho A.F., da Silveira G.G. et al. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget 2015;6(25):20902-20. DOI:10.18632/oncotarget.3939; Lyford-Pike S., Peng S., Young G.D. et al. Evidence for a Role of the PD-1:PD-L1 pathway in immune resistance of HPV- associated head and neck squamous cell carcinoma. Cancer Res 2013;73(6):1733-41. DOI:10.1158/0008-5472.CAN-12-2384; Green S.E., McCusker M.G., Mehra R. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers. Expert Opin Emerg Drugs 2020;25(4):501-14. DOI:10.1080/14728214.2020.1852215; Sunshine J., Taube J.M. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015;23:32-8. DOI:10.1016/j.coph.2015.05.011; Ferris R.L., Blumenschein G., Fayette J. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856-67. DOI:10.1056/NEJMoa1602252; Gulley J.L., Repasky E.A., Wood L.S., Butterfield L.H. Highlights of the 31st Annual Meeting of the Society for Immunotherapy of Cancer (Sitc), 2016. J Immunother Cancer 2017;5(1):55. DOI:10.1186/s40425-017-0262-1; Adusumilli P.S., Cha E., Cornfeld M. et al. New cancer immunotherapy agents in development: a report from an associated program of the 31st annual meeting of the Society for Immunotherapy of Cancer, 2016. J Immunother Cancer 2017;5:50. DOI:10.1186/s40425-017-0253-2; Massarelli E., William W., Johnson F. et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol 2019;5(1):67-73. DOI:10.1001/jamaoncol.2018.4051; Seiwert T.Y., Burtness B., Mehra R. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17(7):956-65. DOI:10.1016/S1470-2045(16)30066-3; Cohen E.E.W., Soulieres D., Le Tourneau C. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156-67. DOI:10.1016/S0140-6736(18)31999-8; Soulieres D., Harrington K.J., Le Tourneau C. et al. Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040. Ann Oncol 2022;33(Suppl_7):S295-322. DOI:10.1016/annonc/annonc1056; Burtness B., Harrington K.J., Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915-28. DOI:10.1016/s0140-6736(19)32591-7; Harrington K.J., Burtness B., Greil R. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. JCO 2023;41(4):790-802. DOI:10.1200/JCO.21.02508.; Colevas A.D., Bahleda R., Braiteh F. et al. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol. 2018;29(11):2247—53. DOI:10.1093/annonc/mdy411; Prendergast G.C., Malachowski W.J., Mondal A. et al. Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer. Int Rev Cell Mol Biol 2018;336:175-203. DOI:10.1016/bs.ircmb.2017.07.004; Godin-Ethier J., Hanafi L.A., Piccirillo C.A., Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 2011;17(22): 6985-91. DOI:10.1158/1078-0432.CCR-11-1331; Nayak-Kapoor A., Hao Z., Sadek R. et al. Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. J Immunother Cancer 2018;6(1):61. DOI:10.1186/s40425-018-0351-9; Mitchell T.C., Hamid O., Smith D.C. et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase i/ii trial (ECHO-202/ KEYNOTE-037). J Clin Oncol 2018;36(32):3223-30. DOI:10.1200/JCO.2018.78.9602; Outh-Gauer S., Alt M., Le Tourneau C. et al. Immunotherapy in head and neck cancers: a new challenge for immunologists, pathologists and clinicians. Cancer Treat Rev 2018;65:54-64. DOI:10.1016/j.ctrv.2018.02.008; Yearley J., Gibson C., Yu N. et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 2017;23:(12):3158-67. DOI:10.1158/1078-0432.CCR-16-1761; Stanley M. HPV-immune response to infection and vaccination. Infect Agent Cancer 2010;5:19. DOI:10.1186/1750-9378-5-19; Whiteside T.L. Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol 2013;3:107. DOI:10.3389/fonc.2013.00107; Nguyen N., Bellile E., Thomas D. et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck 2016;38(7):1074-84. DOI:10.1002/hed.24406; Chow L.Q.M., Haddad R., Gupta S. et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016;34(32):3838-45. DOI:10.1200/jco.2016.68.1478; Bauml J., Seiwert T.Y., Pfister D.G. et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol 2017;35(14):1542-9. DOI:10.1200/JCO.2016.70.1524; Pfister D.G., Haddad R.I., Worden F.P. et al. Biomarkers predictive of response to pembrolizumab in head and neck cancer. Cancer Med 2023;12(6):6603-14. DOI:10.1002/cam4.5434; Kumar B., Cordell K.G., Leeet J.S. al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and Smoking as indicators of response to therapy and survival in oropharyngeal cancer. JCO 2008;26(19):3128-37. DOI:10.1200/JCO.2007.12.7662; Sato F., Ono T., Kawahara A. et al. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. J Clin Pathol 2019;72(8):542-9. DOI:10.1136/jclinpath-2019-205818; Galvis M.M., Borges G.A., Oliveira T.B. et al. Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2020;150:102966. DOI:10.1016/j.critrevonc.2020.102966; https://ogsh.abvpress.ru/jour/article/view/967

Availability: https://ogsh.abvpress.ru/jour/article/view/967
https://doi.org/10.17650/2222-1468-2024-14-1-39-48

A clinical case of the effectiveness of the anti PD-1 inhibitor (prolgolimab) in the treatment of metastatic melanoma ; Клинический пример эффективности ингибитора антиPD-1 (пролголимаб) при лечении метастатической меланомы

Authors: P. V. Golubev, T. I. Deshkina, L. V. Bolotina, E. S. Kuzmina, S. A. Golubeva, I. A. Pokataev, V. N. Galkin, П. В. Голубев, Т. И. Дешкина, Л. В. Болотина, Е. С. Кузьмина, С. А. Голубева, И. А. Покатаев, В. Н. Галкин

Source: Meditsinskiy sovet = Medical Council; № 21 (2024); 140-145 ; Медицинский Совет; № 21 (2024); 140-145 ; 2658-5790 ; 2079-701X

Subject Terms: таргетная терапия, immunotherapy, clinical case, prolgolimab, nivolumab, pembrolizumab, metastatic melanoma, target therapy, иммунотерапия, клинический случай, пролголимаб, ниволумаб, пембролизумаб, метастатическая меланома

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8794/7716; Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Состояние онкологическо помощи населению России в 2022 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2023. 254 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2023/08/sop-2022-el.versiya_compressed.pdf.; Проценко СА, Имянитов ЕН, Малыгин АЮ, Орлов ДО, Семенова АИ, Латипова ДХ и др. Опыт применения пролголимаба в реальной клинической практике. Фарматека. 2021;28(7):51-55. https://doi.org/10.18565/pharmateca.2021.7.51-55.; Ascierto PA, Dummer R, Gogas HJ, Flaherty KT, Arance A, Mandala M et al. Update on tolerability and overall survival in COLUMBUS: landmark analysisof a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenibin patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020;126:33-44. https://doi.org/10.1016/j.ejca.2019.11.016.; Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39. https://doi.org/10.1056/nejmoa1412690.; Curti BD, Faries MB. Recent Advances in the Treatment of Melanoma. N Engl J Med. 2021;384(23):2229-2240. https://doi.org/10.1056/nejmra2034861.; Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowsky P, Lao CD et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535-1546. https://doi.org/10.1056/nejmoa1910836.; Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017;377(14):1345-1356. https://doi.org/10.1056/nejmoa1709684.; Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908-918. https://doi.org/10.1016/s1470-2045(15)00083-2.; Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330. https://doi.org/10.1056/nejmoa1412082.; Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Eur J Cancer. 2018;101:236-243. https://doi.org/10.1016/j.ejca.2018.06.034.; Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239-1251. https://doi.org/10.1016/s1470-2045(19)30388-2.; Строяковский ДЛ, Абдулоева НХ, Демидов ЛВ, Жукова НВ, Новик АВ, Орлова КВ и др. Практические рекомендации по лекарственному лечению меланомы кожи. Злокачественные опухоли. 2022;12(3s2-1):287-306. https://doi.org/10.18027/2224-5057-2022-12-3s2-287-306.; Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-232. https://doi.org/10.1016/j.ejca.2021.02.030.; Beers SA, Glennie MJ, White AL. Influence of immunoglobulin isotype on therapeutic antibody function. Blood. 2016;127(9):1097-1101. https://doi.org/10.1182/blood-2015-09-625343.; Тюляндин СА, Федянин МЮ, Семиглазова ТЮ, Моисеенко ВМ, Одинцова СВ, Алексеев БЯ и др. BCD-100 - первый российский препарат из класса ингибиторов PD-1. Современная онкология. 2017;19(3):5-12. Режим доступа: https://modernonco.orscience.ru/1815-1434/article/view/27133.; Орлова КВ, Федянин МЮ, Симаненков КЭ, Дергунов АС, Гольдшмидт ПР, Сайдуллаева АФ и др. Эффективность 1-й линии терапии пролголимабом у больных метастатической меланомой в реальной клинической практике: промежуточные результаты наблюдательного исследования FORA «FOrteca Real practice Assessment». Современная онкология. 2022;24(4):413-425. https://doi.org/10.26442/18151434.2022.4.202035.; Willsmore ZN, Coumbe BGT, Crescioli S, Reci S, Gupta A, Harris RJ et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. Eur J Immunol. 2021;51(3):544-556. https://doi.org/10.1002/eji.202048747.; Самойленко ИВ, Демидов ЛВ, Моисеенко ФВ, Дворкин МВ, Демидова СА, Проценко СА и др. Эффективность и безопасность препарата нурулимаб+пролголимаб с продолжением терапии пролголимабом по сравнению с монотерапией пролголимабом в качестве 1-й линии терапии пациентов с нерезектабельной или метастатической меланомой: финальные результаты фазы II клинического исследования OBERTON. Современная онкология. 2023;25(3):313-324. https://doi.org/10.26442/18151434.2023.3.202463.; Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol. 2019;37(11):867-875. https://doi.org/10.1200/jco.18.01998.; Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853-1862. https://doi.org/10.1016/s0140-6736(17)31601-x.

Availability: https://www.med-sovet.pro/jour/article/view/8794
https://doi.org/10.21518/ms2024-515

Efficacy of immunotherapy in patients with metastatic melanoma ; Эффективность иммунотерапии у пациентов с метастатической меланомой

Authors: M. A. Lyadova, D. S. Fedorinov, M. V. Nosova, V. M. Tuleiko, A. S. Orlova, D. A. Vozniuk, K. V. Lyadov, V. N. Galkin, М. А. Лядова, Д. С. Федоринов, М. В. Носова, В. М. Тулейко, А. С. Орлова, Д. А. Вознюк, К. В. Лядов, В. Н. Галкин

Contributors: The authors express their gratitude to the team of the Oncology Department No. 1 of the Moscow Center for Rehabilitation Treatment: E.S. Chernyshova, A.A. Kosmynin, R.R. Shakirov, D.S. Shakirova, T.R. Eynullaeva, A.I. Tekeeva, Ya.V. Koroleva, A.A. Ploschik, as well as the administrator of the chemotherapy department No. 1 of the City Clinical Oncology Hospital No. 1 R. Blazhentseva., Авторы выражают благодарность коллективу отделения онкологии №1 Московского центра восстановительного лечения: Е.С. Чернышовой, А.А. Космынину, Р.Р. Шакирову, Д.С. Шакировой, Т.Р. Эйнуллаевой, А.И. Текеевой, Я.В. Королевой, А.А. Площик, а также администратору отделения химиотерапии №1 Городской клинической онкологической больницы №1 Р. Блаженцевой.

Source: Meditsinskiy sovet = Medical Council; № 22 (2023); 146-153 ; Медицинский Совет; № 22 (2023); 146-153 ; 2658-5790 ; 2079-701X

Subject Terms: иммуноопосредованные нежелательные явления, immunotherapy, nivolumab, pembrolizumab, ipilimumab, immune-related adverse events, иммунотерапия, ниволумаб, пембролизумаб, ипилимумаб

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8000/7089; Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208–250. https://doi.org/10.1016/j.jaad.2018.08.055.; Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387. https://doi.org/10.1016/j.ejca.2018.07.005.; Владимирова ЛЮ, Теплякова МА, Попова ИЛ, Абрамова НА, Тихановская НМ, Льянова АА и др. Современные аспекты иммунотерапии ингибиторами контрольных точек при меланоме. Медицинский алфавит. 2022;26:35–40. https://doi.org/10.33667/2078-5631-2022-26-35-40.; Ralli M, Botticelli A, Visconti IC, Angeletti D, Fiore M, Marchetti P et al. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. J Immunol Res. 2020;2020:9235638. https://doi.org/10.1155/2020/9235638.; Ascierto PA, Capone M, Grimaldi AM, Mallardo D, Simeone E, Madonna G et al. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. J Immunother Cancer. 2019;7(1):91. https://doi.org/10.1186/s40425-019-0569-1.; Jenkins RW, Fisher DE. Treatment of Advanced Melanoma in 2020 and Beyond. J Invest Dermatol. 2021;141(1):23–31. https://doi.org/10.1016/j.jid.2020.03.943.; Проценко СА, Имянитов ЕН, Семенова АИ, Латипова ДХ, Новик АВ, Юрлов ДО, Оганесян АП. Современная комбинированная таргетная и иммунотерапия метастатической меланомы кожи. Медицинский совет. 2020;20:54–61. https://doi.org/10.21518/2079-701X-2020-20-54-61.; Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723. https://doi.org/10.1056/NEJMoa1003466.; McDermott D, Haanen J, Chen T, Lorigan P, O’Day S. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013;24(10):2694–2698. https://doi.org/10.1093/annonc/mdt291.; Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526. https://doi.org/10.1056/NEJMoa1104621.; Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33(10):1191–1196. https://doi.org/10.1200/JCO.2014.56.6018.; Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015;33(17):1889–1894. https://doi.org/10.1200/JCO.2014.56.2736.; Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384. https://doi.org/10.1016/S1470-2045(15)70076-8.; McDermott DF, Kluger HM, Sznol M, Carvajal RD, Lawrence DP, Topalian L et al. Long-term survival of ipilimumab-naiv patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. Ann Oncol. 2014;25(4):iv374–iv393. https://doi.org/10.1093/annonc/mdu344.4.; Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. https://doi.org/10.1056/NEJMoa1412082.; Жукова НВ, Антимоник НЮ, Орлова РВ, Беляк НП, Кутукова СИ, Каледина ЕА, Малкова АМ. Иммунотерапия метастатической меланомы: опыт шестилетнего наблюдения. Эффективная фармакотерапия. 2022;18(17):18–21. Режим доступа: https://umedp.ru/articles/immunoterapiya_metastaticheskoy_melanomy_opyt_shestiletnego_nablyudeniya.html?forgot_password=yes&ELEMENT_CODE=immunoterapiya_metastaticheskoy_melanomy_opyt_shestiletnego_nablyudeniya.; Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–2532. https://doi.org/10.1056/NEJMoa1503093.; Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5(7):1008–1019. https://doi.org/10.1001/jamaoncol.2019.0393.; Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24–34. https://doi.org/10.1056/NEJMoa2109970.; Анохина ЕМ, Новик АВ, Проценко СА, Балдуева ИА, Семиглазова ТЮ, Семенова АИ и др. Применение ипилимумаба у больных диссеминированной меланомой в рамках программы расширенного доступа: опыт ФГБУ «НМИЦ онкологии им. И.И. Петрова» Минздрава России. Вопросы онкологии. 2018;64(3):388–393. Режим доступа: https://cyberleninka.ru/article/n/primenenie-ipilimumaba-u-bolnyh-disseminirovannoy-melanomoy-v-ramkah-programmy-rasshirennogo-dostupa-opyt-fgbu-nmits-onkologii-im-i.

Availability: https://www.med-sovet.pro/jour/article/view/8000
https://doi.org/10.21518/ms2023-454

Approaches to the treatment of oligometastatic melanoma in the era of immunotargeted therapy ; Подходы к лечению олигометастатической меланомы в эпоху иммунотаргетной терапии

Authors: E. V. Ledin, V. I. Stolyarov, Е. В. Ледин, В. И. Столяров

Source: Meditsinskiy sovet = Medical Council; № 10 (2024); 22-27 ; Медицинский Совет; № 10 (2024); 22-27 ; 2658-5790 ; 2079-701X

Subject Terms: ипилимумаб, immunotherapy, oligometastatic disease, targeted therapy, metastasectomy, neoadjuvant therapy, adjuvant therapy, pembrolizumab, nivolumab, ipilimumab, иммунотерапия, олигометастатическое заболевание, таргетная терапия, метастазэктомия, неоадъювантная терапия, адъювантная терапия, пембролизумаб, ниволумаб

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8389/7380; Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011;20(1):1–17. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221385/.; Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A et al. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Ann Oncol. 2015;26(11):2267–2274. https://doi.org/10.1093/annonc/mdv324.; Fateeva A, Eddy K, Chen S. Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance. Cancers (Basel). 2024;16(8):1571. https://doi.org/10.3390/cancers16081571.; Boutros A, Croce E, Ferrari M, Gili R, Massaro G, Marconcini R et al. The treatment of advanced melanoma: Current approaches and new challenges. Crit Rev Oncol Hematol. 2024;196:104276. https://doi.org/10.1016/j.critrevonc.2024.104276.; Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127–137. https://doi.org/10.1200/JCO.21.02229.; Urbanski A, Minnemann J, Mauch C, Schmidt T, Kreuzberg N, Schlaak M et al. Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysis. Langenbecks Arch Surg. 2023;408(1):53. https://doi.org/10.1007/s00423-023-02804-9.; McLoughlin JM, Zager JS, Sondak VK. Cytoreductive surgery for melanoma. Surg Oncol Clin N Am. 2007;16(3):683–693. https://doi.org/10.1016/j.soc.2007.04.007.; Enomoto LM, Levine EA, Shen P, Votanopoulos KI. Role of Surgery for Metastatic Melanoma. Surg Clin North Am. 2020;100(1):127–139. https://doi.org/10.1016/j.suc.2019.09.011.; Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8.; Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–166. https://doi.org/10.1016/j.radonc.2020.04.003.; Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–e28. https://doi.org/10.1016/S1470-2045(19)30718-1.; Miller ED, Hitchcock KE, Romesser PB. Oligometastatic Colorectal Cancer: A Review of Definitions and Patient Selection for Local Therapies. J Gastrointest Cancer. 2023;54(4):1116–1127. https://doi.org/10.1007/s12029-022-00900-5.; Kroese TE, van Laarhoven HWM, Nilsson M, Lordick F, Guckenberger M, Ruurda JP et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Eur J Cancer. 2022;166:254–269. https://doi.org/10.1016/j.ejca.2022.02.018.; Jasper K, Stiles B, McDonald F, Palma DA. Practical Management of Oligometastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(6):635–641. https://doi.org/10.1200/JCO.21.01719.; Rogowski P, Roach M 3rd, Schmidt-Hegemann NS, Trapp C, von Bestenbostel R, Shi R et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol. 2021;16(1):50. https://doi.org/10.1186/s13014-021-01776-8.; Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1884–1901. https://doi.org/10.1093/annonc/mdz411.; Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB et al. Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023;41(30):4794–4820. https://doi.org/10.1200/JCO.23.01136.; Versluis JM, Hendriks AM, Weppler AM, Brown LJ, de Joode K, Suijkerbuijk KPM et al. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. Eur J Cancer. 2021;151:72–83. https://doi.org/10.1016/j.ejca.2021.04.003.; Petersen RP, Hanish SI, Haney JC, Miller CC 3rd, Burfeind WR Jr, Tyler DS et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 2007;133(1):104–110. https://doi.org/10.1016/j.jtcvs.2006.08.065.; Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117(20):4740–4706. https://doi.org/10.1002/cncr.26111.; Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547–2555. https://doi.org/10.1245/s10434-012-2398-z.; O’Neill CH, McMasters KM, Egger ME. Role of Surgery in Stage IV Melanoma. Surg Oncol Clin N Am. 2020;29(3):485–495. https://doi.org/10.1016/j.soc.2020.02.010.; Bello DM. Indications for the surgical resection of stage IV disease. J Surg Oncol. 2019;119(2):249–261. https://doi.org/10.1002/jso.25326.; Wollina U, Brzezinski P. The value of metastasectomy in stage IV cutaneous melanoma. Wien Med Wochenschr. 2019;169(13-14):331–338. https://doi.org/10.1007/s10354-018-0630-6.; Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB et al. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Ann Surg Oncol. 2020;27(4):1180–1188. https://doi.org/10.1245/s10434-019-08099-9.; Orlova KV, Ledin E, Zhukova NV, Orlova R, Protsenko S, Novik A et al. The role of surgery (metastasectomy) in advanced BRAF positive melanoma during modern therapy. J Clin Oncol. 2022;40(Suppl. 16):e21512. https://doi.org/10.1200/JCO.2022.40.16_suppl.e21512.; Meacci E, Nachira D, Congedo MT, Ibrahim M, Pariscenti G, Petrella F et al. Surgical Resection of Pulmonary Metastases from Melanoma in Oligometastatic Patients: Results from a Multicentric Study in the Era of Immunoncology and Targeted Therapy. Cancers (Basel). 2023;15(9):2462. https://doi.org/10.3390/cancers15092462.; Ch’ng S, Uyulmaz S, Carlino MS, Pennington TE, Shannon KF, Rtshiladze M et al. Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. Eur J Cancer. 2021;153:8–15. https://doi.org/10.1016/j.ejca.2021.04.037.; Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023;388(9):813–823. https://doi.org/10.1056/NEJMoa2211437.; Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. https://doi.org/10.1038/nature13954.; Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–3895. https://doi.org/10.1002/j.1460-2075.1992.tb05481.x.; Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–824. https://doi.org/10.1093/intimm/dxm057.; Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–12297. https://doi.org/10.1073/pnas.192461099.; Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. https://doi.org/10.1126/science.aaa8172.; Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016;6(12):1382–1399. https://doi.org/10.1158/2159-8290.CD-16-0577.; Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655–1661. https://doi.org/10.1038/s41591-018-0198-0.; Mangla A, Lee C, Mirsky MM, Wang M, Rothermel LD, Hoehn R et al. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis. JAMA Oncol. 2024;10(5):612–620. https://doi.org/10.1001/jamaoncol.2023.7333.; Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186–197. https://doi.org/10.1200/JCO.22.01763.; Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V et al. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. J Clin Oncol. 2023;41(2):212–221. https://doi.org/10.1200/JCO.21.02961.; Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018;19(2):181–193. https://doi.org/10.1016/S1470-2045(18)30015-9.; Menzies AM, Saw RPM, Lo SN, Gonzalez M, Ch’ng S, Nieweg OE et al. Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Longterm results from the NeoCombi trial. J Clin Oncol. 2022;40(Suppl. 16):9580. https://doi.org/10.1200/JCO.2022.40.16_suppl.9580.

Availability: https://www.med-sovet.pro/jour/article/view/8389
https://doi.org/10.21518/ms2024-236

The role of cetuximab in treatment of squamous cell carcinoma of the head and neck ; Роль лекарственной терапии в лечении плоскоклеточного рака головы и шеи

Authors: I. A. Koroleva, M. V. Kopp, И. А. Королева, М. В. Копп

Source: Meditsinskiy sovet = Medical Council; № 21 (2024); 30-40 ; Медицинский Совет; № 21 (2024); 30-40 ; 2658-5790 ; 2079-701X

Subject Terms: химиотерапия, epidermal growth factor receptor (EGFR), cetuximab, target therapy, chemotherapy, рецептор эпидермального фактора роста (EGFR), цетуксимаб, пембролизумаб, ниволумаб, таргетная терапия

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8781/7705; Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Состояние онкологической помощи населению России в 2023 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2024. 262 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2024/06/sop-2023-elektronnaya-versiya.pdf.; Chang CP, Chang SC, Chuang SC, Berthiller J, Ferro G, Matsuo K et al. Age at start of using tobacco on the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium (INHANCE). Cancer Epidemiol. 2019;63:101615. https://doi.org/10.1016/j.canep.2019.101615.; Fernandes Q, Merhi M, Raza A, Inchakalody VP, Abdelouahab N, Zar Gul AR et al. Role of Epstein–Barr Virus in the Pathogenesis of Head and Neck Cancers and Its potential as an Immunotherapeutic Target. Front Oncol. 2018;8:257. https://doi.org/10.3389/fonc.2018.00257.; Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015;33(29):3235–3242. https://doi.org/10.1200/JCO.2015.61.6995.; Бычков ВА, Уразова ЛН, Никитина ЕГ, Черемисина ОВ, Чижевская СЮ. Папилломавирусная инфекция и прогрессия опухолей головы и шеи. Инфекция и иммунитет. 2014;4(2):162-166. Режим доступа: https://iimmun.ru/iimm/article/view/167/166.; Alfouzan AF. Head and neck cancer pathology: Old world versus new world disease. Niger J Clin Pract. 2019;22(1):1-8. https://doi.org/10.4103/njcp.njcp_310_18.; Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660.; Li Y, Hu C. Early Death Incidence and Prediction Among Patients With Hypopharynx Squamous Cell Carcinomas. Ear Nose Throat J. 2023;1455613231192282. https://doi.org/10.1177/01455613231192282.; van den Besselaar BN, Sewnaik A, Hoesseini A, Dorr MC, Baatenburg de Jong RJ, Offerman MPJ. Causes and Ways of Death in Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2024;150(4):303-310. https://doi.org/10.1001/jamaoto.2023.4694.; Zapata I, Alvarez M, Hidalgo R, Pajares B, Garcia-Anaya MJ, Toledo MD et al. Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy. BMC Cancer. 2019;19(1):1241. https://doi.org/10.1186/s12885-019-6427-1.; Болотина ЛВ, Владимирова ЛЮ, Деньгина НВ, Кутукова СИ, Новик АВ, Романов ИС. Практические рекомендации по лекарственному лечению опухолей головы и шеи. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли. 2023;13(3s2):100-119. https://doi.org/10.18027/2224-5057-2023-13-3s2-1-100-119.; Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4-14. https://doi.org/10.1016/j.radonc.2009.04.014.; León X, Hitt R, Constenla M, Rocca A, Stupp R, Kovács AF et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinumbased chemotherapy. Clin Oncol. 2005;17(6):418-424. https://doi.org/10.1016/j.clon.2005.02.014.; Moosmann N, Heinemann V. Cetuximab in the treatment of metastatic colorectal cancer. Expert Opin Biolog Ther. 2007;7(2):243-256. https://doi.org/10.1517/14712598.7.2.243.; Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90(11):824-832. https://doi.org/10.1093/jnci/90.11.824.; Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993;53(19):4637-4642. Available at: https://pubmed.ncbi.nlm.nih.gov/8402640/.; Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFR antibody C225 and radiation. Cancer Biother Radiopharm. 1999;14(6):451-463. https://doi.org/10.1089/cbr.1999.14.451.; Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5568–5577. https://doi.org/10.1200/JCO.2005.07.119.; Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5578-5587. https://doi.org/10.1200/JCO.2005.07.120.; Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171-2177. https://doi.org/10.1200/JCO.2006.06.7447.; Specenier PM, Vermorken JB. Targeted therapies in head and neck cancer. Target Oncol. 2007;2(2):73-88. https://doi.org/10.1007/s11523-007-0048-3.; Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23(34):8646-8654. https://doi.org/10.1200/JCO.2005.02.4646.; Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-1127. https://doi.org/10.1056/NEJMoa0802656.; Guigay J, Fayette J, Dillies AF, Sire C, Kerger JN, Tennevet I et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann Oncol. 2015;26(9):1941-1947. https://doi.org/10.1093/annonc/mdv268.; Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463-475. https://doi.org/10.1016/S1470-2045(20)30755-5.; Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2007;355(9208):949-955. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)90011-4/abstract.; Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578. https://doi.org/10.1056/NEJMoa053422.; Budach W, Bölke E, Horney B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med. 2007;357(5):514-515. https://doi.org/10.1056/NEJMc071075.; Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940-2950. https://doi.org/10.1200/JCO.2013.53.5633.; Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamouscell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014;32(23):2486-2495. https://doi.org/10.1200/JCO.2013.53.9163.; Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450-461. https://doi.org/10.1016/j.ccell.2015.03.001.; Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015;75(3):508-518. https://doi.org/10.1158/0008-5472.CAN-14-1215.; Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73(1):128-138. https://doi.org/10.1158/0008-5472.CAN-12-2606.; Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L et al. Nivolumab for recurrent squamous cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-1867. https://doi.org/10.1056/NEJMoa1602252.; Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156-167. https://doi.org/10.1016/S0140-6736(18)31999-8.; Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. 2023;41(4):790-802. https://doi.org/10.1200/JCO.21.02508.; Saleh K, Vinches M, Safta I, Guiard E, Marret G, Vion R et al. Taxanes plus cetuximab with or without platinum chemotherapy after progressionon immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2022;40(16 Suppl.):6036. https://doi.org/10.1200/JCO.2022.40.16_suppl.6036.; Королева ИА, Болотина ЛВ, Гладков ОА, Горбунова ВА, Когония ЛМ, Круглова ЛС и др. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2023;13(3s2):108-131. https://doi.org/10.18027/2224-5057-2023-13-3s2-2-108-131.; Kafatos G, Dube S, Burdon P, Demonty G, Flinois A, Leclerc M et al. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients’ Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers. Clin Colorectal Cancer. 2020;19(2):100-108.e9. https://doi.org/10.1016/j.clcc.2020.01.001.; Petrelli F, Borgonovo K, Cabiddu M, Coinu A, Ghilardi M, Lonati V, Barni S. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1166-1174. https://doi.org/10.1111/bjd.14756.; Мудунов АМ, Пак МБ, Вольф ЛЯ. Роль нутритивной поддержки в лечении опухолей головы и шеи: клинический случай. Опухоли головы и шеи. 2022;12(3):86-94. https://doi.org/10.17650/2222-1468-2022-12-3-86-94.; Сытов АВ, Зузов СА, Кукош МЮ, Лейдерман ИН, Потапов АЛ, Хотеев АЖ. Практические рекомендации по нутритивной поддержке онкологических больных. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2023;13(3s2):132-142. https://doi.org/10.18027/2224-5057-2023-13-3s2-2-132-142.

Availability: https://www.med-sovet.pro/jour/article/view/8781
https://doi.org/10.21518/ms2024-513

Рак предстательной железы

Authors: Д. А. Носов, М. И. Волкова, О. А. Гладков, Е. В. Карабина, В. В. Крылов, В. Б. Матвеев, С. В. Усычкин, Т. Митин

Source: Malignant tumours; Том 14, № 3s2-2 (2024); 242-266 ; Злокачественные опухоли; Том 14, № 3s2-2 (2024); 242-266 ; 2587-6813 ; 2224-5057

Subject Terms: пембролизумаб, андрогенная депривация, доцетаксел, кабазитаксел, абиратерона ацетат, апалутамид, даролутамид, энзалутамид, радия хлорид [ 223Ra], 177Lu-ПСМА, 225Ac-ПСМА, олапариб

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1391/996; https://www.malignanttumors.org/jour/article/view/1391

Availability: https://www.malignanttumors.org/jour/article/view/1391
https://doi.org/10.18027/2224-5057-2024-14-3s2-1.2-10

Злокачественные опухоли печени и желчевыводящей системы

Authors: В. В. Бредер, И. С. Базин, П. В. Балахнин, Е. В. Ледин, Б. М. Медведева, Ф. В. Моисеенко, Е. А. Мороз, В. В. Петкау, И. В. Погребняков, И. А. Покатаев

Source: Malignant tumours; Том 14, № 3s2-1 (2024); 358-403 ; Злокачественные опухоли; Том 14, № 3s2-1 (2024); 358-403 ; 2587-6813 ; 2224-5057

Subject Terms: пембролизумаб, цирроз печени, BCLC, ТАХЭ, РЧА, абляция, иммунотерапия, атезолизумаб, бевацизумаб, сорафениб, регорафениб, ленватиниб, кабозантиниб, рамуцирумаб, ниволумаб, ипилимумаб, тремелимумаб, АФП, рак билиарного тракта, холангиокарцинома, рак желчного пузыря, химиотерапия, химиолучевая терапия, CA19‑9, дурвалумаб

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1373/978; https://www.malignanttumors.org/jour/article/view/1373

Availability: https://www.malignanttumors.org/jour/article/view/1373
https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-17

Современные возможности иммунотерапии меланомы: обзор литературы

Authors: Cherchenko, K.D.

Source: Практична онкологія-Praktična onkologìâ; Том 3, № 1 (2020); 46-52
Practical oncology; Том 3, № 1 (2020); 46-52
Практическая онкология-Praktična onkologìâ; Том 3, № 1 (2020); 46-52

Subject Terms: кожная меланома, распространенные и метастатические формы, иммунотерапия, ингибиторы PD-1/PD-L1, ниволумаб, пембролизумаб, обзор, шкірна меланома, поширені та метастатичні форми, імунотерапія, інгібітори PD-1/PD-L1, ніволумаб, пембролізумаб, огляд, cutaneous melanoma, advanced and metastatic forms, immunotherapy, PD-1/PD-L1 inhibitors, nivolumab, pembrolizumab, review, 3. Good health

File Description: application/pdf

Access URL: http://oncology.zaslavsky.com.ua/article/view/209931

Ингибиторы контрольных точек и классическая лимфома Ходжкина: эффективность и безопасность пембролизумаба при рецидивах и рефрактерном течении опухоли (опыт ФГБУ «НМХЦ им. Н.И. Пирогова» Минздрава России)

Authors: Anna E. Bannikova, VS Bogatyrev, A.A. Mamedova, Elena G. Smirnova, AA Samoilova, A.A. Spornik, NE Mochkin, Vladislav Olegovich Sarzhevskii, E.A. Demina, V. Ya. Melnichenko

Source: Клиническая онкогематология, Vol 14, Iss 1 (2021)

Subject Terms: пембролизумаб, 03 medical and health sciences, 0302 clinical medicine, иммунотерапия, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ингибиторы контрольных точек, RC254-282, классическая лимфома Ходжкина, 3. Good health

Access URL: https://doaj.org/article/1e0ba98523784f0e830bb56d39b094ab

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria) ; Токсичность, ассоциированная с ингибиторами иммунных контрольных точек: анализ иммуноопосредованных нежелательных явлений при применении биоаналога пембролизумаба (Пемброриа)

Authors: M. Yu. Fedyanin, A. V. Snegovoy, V. V. Breder, Yu. N. Linkova, A. V. Zinkina-Orikhan, S. B. Setkina, S. N. Fogt, V. S. Chistiakov, N. A. Kravtsova, М. Ю. Федянин, А. В. Снеговой, В. В. Бредер, Ю. Н. Линькова, А. В. Зинкина-Орихан, С. Б. Сеткина, С. Н. Фогт, В. С. Чистяков, Н. А. Кравцова

Contributors: The study sponsor is BIOCAD JSC (Russia)., Спонсор исследования — AO «БИОКАД» (Россия).

Source: Safety and Risk of Pharmacotherapy; Том 11, № 2 (2023); 215-230 ; Безопасность и риск фармакотерапии; Том 11, № 2 (2023); 215-230 ; 2619-1164 ; 2312-7821

Subject Terms: клинические исследования, pembrolizumab, biosimilar, PD-1 inhibitor, immune-related adverse events, immune-mediated adverse reactions, immune-checkpoint inhibitors, immunotherapy, clinical trials, пембролизумаб, биоаналог, PD-1-ингибитор, иммуноопосредованные нежелательные явления, иммуноопосредованные нежелательные реакции, ингибиторы иммунных контрольных точек, иммунотерапия

File Description: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/360/737; https://www.risksafety.ru/jour/article/view/360/788; https://www.risksafety.ru/jour/article/downloadSuppFile/360/347; Stege H, Haist M, Nikfarjam U, Schultheis M, Heinz J, Pemler S, et al. The status of adjuvant and neoadjuvant melanoma therapy, new developments and upcoming challenges. Target Oncol. 2021;16(5):537–52. https://doi.org/10.1007/s11523-021-00840-3; Qiu Z, Chen Z, Zhang C, Zhong W. Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. Exp Hematol Oncol. 2019;8:19. https://doi.org/10.1186/s40164-019-0143-z; Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel). 2021;13(1):131. https://doi.org/10.3390/cancers13010131; Márquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, González-Cao M, Martín-Algarra S. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med. 2015;3(18):267. PMID: 26605313; Feng MY, Chan LL, Chan SL. Drug treatment for advanced hepatocellular carcinoma: first-line and beyond. Curr Oncol. 2022;29(8):5489–507. https://doi.org/10.3390/curroncol29080434; Resch I, Bruchbacher A, Franke J, Fajkovic H, Remzi M, Shariat SF, et al. Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines. ESMO Open. 2021;6(4):100122. https://doi.org/10.1016/j.esmoop.2021.100122; Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8. https://doi.org/10.1001/jamaoncol.2018.3923; El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1–12. https://doi.org/10.1016/j.critrevonc.2017.09.002; Vaddepally R, Doddamani R, Sodavarapu S, Madam NR, Katkar R, Kutadi AP, et al. Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)—their incidence, management, multi-organ irAEs, and rechallenge. Biomedicines. 2022;10(4):790. https://doi.org/10.3390/biomedicines10040790; Olsen TA, Zhuang TZ, Caulfield S, Martini DJ, Brown JT, Carthon BC, et al. Advances in knowledge and management of immune-related adverse events in cancer immunotherapy. Front Endocrinol (Lausanne). 2022;13:779915. https://doi.org/10.3389/fendo.2022.779915; Allouchery M, Beuvon C, Pérault-Pochat MC, Roblot P, Puyade M, Martin M. Safety of immune check-point inhibitor resumption after interruption for immune-related adverse events, a narrative review. Cancers (Basel). 2022;14(4):955. https://doi.org/10.3390/cancers14040955; Kubo T, Hirohashi Y, Tsukahara T, Kanaseki T, Murata K, Morita R, Torigoe T. Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy. Immunol Med. 2022;45(2):108–18. https://doi.org/10.1080/25785826.2021.1976942; Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504–15. https://doi.org/10.1038/s41571-020-0352-8; Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018;128(2):715–20. https://doi.org/10.1172/JCI96798; Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci. 2018;109(11):3583–90. https://doi.org/10.1111/cas.13800; Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer. 2017;123(S11):2143–53. https://doi.org/10.1002/cncr.30444; Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66(5):581–92. https://doi.org/10.1007/s00262-017-1962-6; Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45. https://doi.org/10.1126/scitranslmed.3008002; Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. https://doi.org/10.1038/s41572-020-0160-6; Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391. https://doi.org/10.1038/ncomms10391; Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011;18(13):3579–85. https://doi.org/10.1245/s10434-011-1976-9; Valpione S, Pasquali S, Campana LG, Piccin L, Mocellin S, Pigozzo J, Chiarion-Sileni V. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med. 2018;16(1):94. https://doi.org/10.1186/s12967-018-1467-x; Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother. 2019;68(6):917–26. https://doi.org/10.1007/s00262-019-02321-z; Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018;52(Pt 2):228–40. https://doi.org/10.1016/j.semcancer.2018.01.008; Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):583–9. https://doi.org/10.1093/annonc/mdw640; Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. 2019;5(3):376–83. https://doi.org/10.1001/jamaoncol.2018.5860; Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127–34. https://doi.org/10.1212/WNL.0000000000004359; Clavel T, Gomes-Neto JC, Lagkouvardos I, Ramer-Tait AE. Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes. Immunol Rev. 2017;279(1):8–22. https://doi.org/10.1111/imr.12578; Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO, Shah AA. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology (Oxford). 2019;58(3):476–80. https://doi.org/10.1093/rheumatology/key358; Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer. 2019;107:8–14. https://doi.org/10.1016/j.ejca.2018.11.009; Fountzilas E, Lampaki S, Koliou GA, Koumarianou A, Levva S, Vagionas A, et al. Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. Cancer Immunol Immunother. 2022;71(2):327–37. https://doi.org/10.1007/s00262-021-02985-6; Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21–9. https://doi.org/10.1016/j.ejca.2017.12.008; Robert C, Hwu WJ, Hamid O, Ribas A, Weber JS, Daud AI, et al. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma. Eur J Cancer. 2021;144:182–91. https://doi.org/10.1016/j.ejca.2020.11.010; Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98(2):344–51. https://doi.org/10.1016/j.ijrobp.2017.02.003; Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365–6. https://doi.org/10.1056/NEJMc1302338; Vizcarrondo FR, Patel SP, Pennell NA, Pakkala S, West H, Kratzke R, et al., Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 2016;27(Suppl 6):vi416–54. https://doi.org/10.1093/annonc/mdw383.91; Ahn M-J, Yang J, Yu H, Saka H, Ramalingam S, Goto K, et al. 136O: osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. Journal of Thoracic Oncology. 2016;11(4):S115. https://doi.org/10.1016/S1556-0864(16)30246-5; Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(12):1692–700. https://doi.org/10.2215/CJN.00990119; Raghavan R, Shawar S. Mechanisms of drug-induced interstitial nephritis. Adv Chronic Kidney Dis. 2017;24(2):64–71. https://doi.org/10.1053/j.ackd.2016.11.004; Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, et al. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer. 2019;7(1):242. https://doi.org/10.1186/s40425-019-0714-x; Проценко СА, Антимоник НЮ, Берштейн Л.М, Жукова НВ, Новик АВ, Носов ДА и др. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Злокачественные опухоли. 2022;10(3s2):168–99. https://doi.org/10.18027/2224-5057-2020-10-3s2-50; Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–42. https://doi.org/10.1093/annonc/mdx225; Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021;80(1):36–48. https://doi.org/10.1136/annrheumdis-2020-217139; Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw. 2020;18(3):230–41. https://doi.org/10.6004/jnccn.2020.0012; Ito M, Fujiwara S, Fujimoto D, Mori R, Yoshimura H, Hata A, et al. Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient. Ann Oncol. 2017;28(9):2318–9. https://doi.org/10.1093/annonc/mdx252; Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, et al. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. Eur J Cancer. 2018;102:49–51. https://doi.org/10.1016/j.ejca.2018.07.125; Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N Engl J Med. 2019;380(24):2375–6. https://doi.org/10.1056/NEJMc1903064; Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377–9. https://doi.org/10.1056/NEJMc1901677; Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76(12):2061–4. https://doi.org/10.1136/annrheumdis-2017-211560; Комиссарова ВА. Меры минимизации рисков в фармаконадзоре: обзор отечественного и зарубежного опыта. Качественная клиническая практика. 2019;(3):33–43. https://doi.org/10.24411/2588-0519-2019-10081; Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. https://doi.org/10.1056/NEJMoa1503093; https://www.risksafety.ru/jour/article/view/360

Availability: https://www.risksafety.ru/jour/article/view/360
https://doi.org/10.30895/2312-7821-2023-11-2-360

Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy ; Обновленный фармакоэкономический анализ эффективности применения препарата атезолизумаб в сравнении с другими ингибиторами PD-1 у пациентов с распространенным немелкоклеточным раком легкого после предшествующей химиотерапии

Authors: S. K. Zyryanov, I. N. Dyakov, С. К. Зырянов, И. Н. Дьяков

Source: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 16, No 3 (2023); 422-430 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 16, No 3 (2023); 422-430 ; 2070-4933 ; 2070-4909

Subject Terms: анализ влияния на бюджет, NSCLC, second line therapy, third line therapy, checkpoint inhibitors, PD-1/PD-L1 inhibitors, atezolizumab, pembrolizumab, nivolumab, cost minimization analysis, budget impact analysis, НМРЛ, вторая линия терапии, третья линия терапии, ингибиторы контрольных точек, ингибиторы PD-1/PD-L1, атезолизумаб, пембролизумаб, ниволумаб, анализ минимизации затрат

File Description: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/894/498; Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.) Состояние онкологической помощи населению России в 2022 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022: 239 с.; Злокачественное новообразование бронхов и легкого. Клинические рекомендации. 2022. URL: https://cr.minzdrav.gov.ru/recomend/30_4 (дата обращения 03.09.2023).; Инструкция по медицинскому применению лекарственного препарата Китруда®. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=88450c76-24e5-43ee-bbd3-afd10dc1e7c8&t= (дата обращения 03.09.2023).; Инструкция по медицинскому применению лекарственного препарата Опдиво® URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f6ac1a6a-9f33-4eaa-a603-b2928d720378&t= (дата обращения 03.09.2023).; Инструкция по медицинскому применению лекарственного препарата Тецентрик®. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c210e8ba-5f80-4dc6-90bc-98e51fb468ed&t= (дата обращения 03.09.2023).; Зырянов С.К., Дьяков И.Н. Фармакоэкономическая эффективность применения препарата атезолизумаб в сравнении с другими ингибиторами PD-1 у пациентов с распространенным немелкоклеточным раком легкого после предшествующей химиотерапии. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (1): 5–12. https://doi.org/10.17749/20704909.2020.13.1.5-12.; Créquit P., Chaimani A., Yavchitz A., et al. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis. BMC Med. 2017; 15 (1): 193. https://doi.org/10.1186/s12916-017-0954-x.; Rittmeyer A., Barlesi F., Waterkamp D., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389 (10066): 255–65. https://doi.org/10.1016/S01406736(16)32517-X.; НМИЦ oнкологии им. Н.Н. Блохина. Прейскурант. URL: https://www.ronc.ru/platnye-uslugi/prays-list-uslug/ (дата обращения 03.09.2023).; Постановление Правительства РФ от 28.08.2014 № 871 «Об утверждении Правил формирования перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи». URL: https://base.garant.ru/70728348/ (дата обращения 03.09.2023).; https://www.pharmacoeconomics.ru/jour/article/view/894

Availability: https://www.pharmacoeconomics.ru/jour/article/view/894
https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.211

Complete radiological response when using pembrolizumab in the mono mode in the 2nd-line drug therapy of MSI-h / dMMR-positive advanced endometrial cancer. A clinical case ; Полный радиологический ответ при использовании пембролизумаба в монорежиме во 2-й линии лекарственной терапии MSI-h / dMMR-положительного распространенного рака эндометрия. Клинический случай

Authors: A. D. Darenskaya, B. M. Medvedeva, A. A. Rumyantsev, A. S. Tyulyandina, А. Д. Даренская, Б. М. Медведева, А. А. Румянцев, А. С. Тюляндина

Source: Surgery and Oncology; Том 13, № 3 (2023); 49-56 ; Хирургия и онкология; Том 13, № 3 (2023); 49-56 ; 2949-5857

Subject Terms: таргетная терапия, microsatellite instability, MSI, MMR, pembrolizumab, immunotherapy, chemotherapy, targeted therapy, микросателлитная нестабильность, пембролизумаб, иммунотерапия, химиотерапия

File Description: application/pdf

Relation: https://www.onco-surgery.info/jour/article/view/646/439; Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с.; Miller D.S., Filiaci V.L., Mannel R.S. et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/ GOG0209). J Clin Oncol 2020;38(33):3841–50. DOI:10.1200/JCO.20.01076; Miller D., Filiaci V., Fleming G. et al. Late-breaking abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2012;125(3):771. DOI:10.1016/j.ygyno.2012.03.034; Нечушкина В.М., Коломиец Л.А., Кравец О.А. и др. Практические рекомендации по лекарственному лечению рака тела матки и сарком матки. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2022;12(3):260–75. DOI:10.18027/2224-5057-2022-12-3s2-260-275; National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine Neoplasms. Version 1.2023. December 22, 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf; Lorusso D., Ferrandina G., Colombo N. et al. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III–IV) or recurrent endometrial cancer: The MITO END-2 trial. J Clin Oncol 2015;33 (15 Suppl): 5502. DOI:10.1200/jco.2015.33.15_suppl.5502; Аghajanian C., Filiaci V.L., Dizon D.S. et al. A randomized phase II study of paclitaxel/carboplatin/ bevacizumab, paclitaxel/ carboplatin/temsirolimus and ixabepilone/carboplatin/ bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. J Clin Oncol 2015;33(Suppl): Abstract 5500.; Fader A.N., Roque D.M., Siegel E. et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol 2018;36(20):2044–51. DOI:10.1200/JCO.2017.76.5966; Lincoln S., Blessing J.A., Lee R.B. et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2003;88(3):277–81. DOI:10.1016/S0090-8258(02)00068-9; Homesley H.D., Meltzer N.P., Nieves L. et al. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer. Int J Clin Oncol 2008;13(1):62–5. DOI:10.1007/s10147-007-0731-5; Garcia A.A., Blessing J.A., Nolte S. et al. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group. Gynecol Oncol 2008;111(1):22–6. DOI:10.1016/j.ygyno.2008.06.013; Tait D.L., Blessing J.A., Hoffman J.S. et al. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study. Gynecol Oncol 2011;121(1):118–2. DOI:10.1016/j.ygyno.2010.11.027; Fracasso P.M., Blessing J.A., Molpus K.L. et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2006;103(2):523–6. DOI:10.1016/j.ygyno.2006.03.043; Makker V., Hensley M.L., Zhou Q. et al. Treatment of Advanced or Recurrent Endometrial Carcinoma with Doxorubicin in Patients Progressing After Paclitaxel/Carboplatin: Memorial Sloan-Kettering Cancer Center Experience From 1995 to 2009. Int J Gynecol Cancer 2013;23(5):929–34. DOI:10.1097/IGC.0b013e3182915c20; Moreira E., Paulino E., Ingles Garces Á.H. et al. Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA). Med Oncol 2018;35(3):20. DOI:10.1007/s12032-018-1086-7; Muggia F.M., Blessing J.A., Sorosky J. et al. Phase II Trial of the Pegylated Liposomal Doxorubicin in Previously Treated Metastatic Endometrial Cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2002;20(9):2360–4. DOI:10.1200/JCO.2002.08.171; Sutton G.P., Blessing J.A., Homesley H.D. et al. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Cancer 1994;73(5):1453–5. DOI:10.1002/1097-0142(19940301)73:53.0.co;2-x; Rose P.G., Blessing J.A., Lewandowski G.S. et al. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 1996;63(1):101–4. DOI:10.1006/gyno.1996.0286; Miller D.S., Blessing J.A., Lentz S.S. et al. A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 2002;87(3):247–51. DOI:10.1006/gyno.2002.6804; Miller D.S., Blessing J.A., Drake R.D. et al. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol 2009;115(3):443–6. DOI:10.1016/j.ygyno.2009.09.004; Dizon D.S., Blessing J.A., McMeekin D.S. et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P. J Clin Oncol 2009;27(19):3104–8. DOI:10.1200/JCO.2008.20.6995; Markman M., Fowler J. Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. Gynecol Oncol 2004;92(1):180–2. DOI:10.1016/j.ygyno.2003.10.019; Moore K.N., Tian C., McMeekin S. et al. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? Cancer 2010;116(23):5407–14. DOI:10.1002/cncr.25480; Nagao S., Nishio S., Michimae H. et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol 2013;131(3):567–73. DOI:10.1016/j.ygyno.2013.09.021; Slomovitz B.M., Jiang Y., Yates M.S. et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2015;33(8):930–6. DOI:10.1200/JCO.2014.58.3401; Coleman R.L., Sill M.W., Lankes H.A. et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2012;127(3):538–43. DOI:10.1016/j.ygyno.2012.08.020; Makker V., Filiaci V.L., Chen L.M. et al. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N. Gynecol Oncol 2015;138(1):24–9. DOI:10.1016/j.ygyno.2015.04.006; Aghajanian C., Sill M.W., Darcy K.M. et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 2011;29(16):2259–65. DOI:10.1200/JCO.2010.32.6397; Castonguay V., Lheureux S., Welch S. et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol 2014;134(2):274–80. DOI:10.1016/j.ygyno.2014.05.016; Nimeiri H.S., Oza A.M., Morgan R.J. et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010;117(1):37–40. DOI:10.1016/j.ygyno.2010.01.013; Powell M.A., Sill M.W., Goodfellow P.J. et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2014;135(1):38–43. DOI:10.1016/j.ygyno.2014.07.083; Dizon D.S, Sill M.W., Schilder J.M. et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 2014;135(3):441–5. DOI:10.1016/j.ygyno.2014.10.001; Bender D., Sill M.W., Lankes H.A. et al. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015;138(3):507–12. DOI:10.1016/j.ygyno.2015.07.018; Moore K.N., Sill M.W., Tenney M.E. et al. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/ recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol 2015;138(3):513–8. DOI:10.1016/j.ygyno.2015.07.006; Leslie K.K., Sill M.W., Fischer E. et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2013;129(3):486–94. DOI:10.1016/j.ygyno.2013.02.019; Oza A.M., Eisenhauer E.A., Elit L. et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008;26(26):4319–25. DOI:10.1200/JCO.2007.15.8808; Slomovitz В.M., Chelariu-Raicu А., Schmeler K.M. et al. Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Int J Gynecol Cancer 2020;30(11):1733–7. DOI:10.1136/ijgc-2020-001859; Fleming G.F., Sill M.W., Darcy K.M. et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2010;116(1):15–20. DOI:10.1016/j.ygyno.2009.09.025; Leslie K.K., Sill M.W., Lankes H.A. et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012;127(2):345–50. DOI:10.1016/j.ygyno.2012.07.127; Slomovitz B.M., Lu K.H., Johnston T. et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010;116(23):5415–9. DOI:10.1002/cncr.25515; Ray-Coquard I., Favier L., Weber B. et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer 2013;108(9):1771–7. DOI:10.1038/bjc.2013.183; Oza A.M., Elit L., Tsao M.S. et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29(24):3278–85. DOI:10.1200/JCO.2010.34.1578; Fleming G.F., Filiaci V.L., Marzullo B. et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2014;132(3):585–92. DOI:10.1016/j.ygyno.2014.01.015; Colombo N., McMeekin D.S., Schwartz P.E. et al. Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial. Br J Cancer 2013;108(5):1021–6. DOI:10.1038/bjc.2013.59; Oza A.M., Pignata S., Poveda A. et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol 2015;33(31):3576–82. DOI:10.1200/JCO.2014.58.8871; Alvarez E.A., Brady W.E., Walker J.L. et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2013;129(1):22–7. DOI:10.1016/j.ygyno.2012.12.022; Lorenzi M., Amonkar M., Zhang J. et al. Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review. J Oncol 2020;2020:1–17. DOI:10.1155/2020/1807929; Marabelle A., Fakih M., Lopez J. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21(10):1353–65. DOI:10.1016/S1470-2045(20)30445-9; Le D.T., Uram J.N., Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372(26):2509–20. DOI:10.1056/NEJMoa1500596; Marabelle A., Le D.T., Ascierto P.A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38(1):1–10. DOI:10.1200/JCO.19.02105; Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ, Merck Sharp & Dohme, 2018.; Arora E., Masab M., Mittar P. et al. Role of immune checkpoint inhibitors in advanced or recurrent endometrial cancer. Cureus 2018;10:e2521.; Diaz L.A., Marabelle A., Delord J.P. et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncology 2017;35(15):3071. DOI:10.1200/JCO.2017.35.15_suppl.3071; O’Malley D.M., Bariani G.M., Cassier P.A. et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol 2022;40(7):752–61. DOI:10.1200/JCO.21.01874; Lee C.-H., Shah A.Y., Hsieh J.J. et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol 2020;38(15 Suppl): abstr 5008. DOI:10.1200/JCO.2020.38.15_suppl.5008

Availability: https://www.onco-surgery.info/jour/article/view/646
https://doi.org/10.17650/2949-5857-2023-13-3-49-56